Influenza
Conditions
Keywords
Pandemic, GSK Bio's influenza vaccine GSK2340274A, H1N1, Influenza
Brief summary
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
Interventions
Intramuscular injections
BIOLOGICALGSK Biologicals' FluLaval®
Intramuscular injection
BIOLOGICALGSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
Intramuscular injections
BIOLOGICALPlacebo (saline)
Intramuscular injection
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits). * Written informed consent obtained from the subject. * Male or female adults, 19-40 years of age at the time of the first vaccination. * Body weight of at least 110 pounds (49.9 kg). * Safety laboratory tests results within the parameters specified by protocol. * Satisfactory baseline medical assessment by physical examination (stable health status with no exclusionary conditions). Stable health status is defined as the absence of a health event satisfying the definition of a serious adverse event, or a change in an ongoing drug therapy due to therapeutic failure or symptoms of drug toxicity, within one month prior to enrollment. * Comprehension of the study requirements, ability to comprehend and comply with procedures for collection of safety data, expressed availability for the required study period, and ability and willingness to attend scheduled visits as documented by signature on the informed consent document. * Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line, or mobile, but NOT a pay phone or other multiple-user device (i.e., a common-use phone serving multiple rooms or apartments). * Female subjects of non-childbearing potential may be enrolled in the study. * Non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy, or post-menopause. * Female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of vaccination, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series
Exclusion criteria
* Previous vaccination with an A/California/7/2009 (H1N1)v-like virus vaccine * A medical history of physician-confirmed infection with an A/California/7/2009 (H1N1)v-like virus. * Prior receipt at any time of any seasonal influenza vaccine. * Planned administration of any vaccine not foreseen by the study protocol (including any influenza vaccine other than the study vaccine) between Days 0 and the Day 164 phlebotomy. * Administration of any licensed vaccine within 30 days before the first study vaccine dose. * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Receipt of systemic glucocorticoids (e.g., prednisone ≥ 0.5 mg/kg/day, or ≥ 10 mg/day \[whichever is less\] for more than 14 consecutive days) within one month prior to study enrolment, or any other cytotoxic or immunosuppressive drug within six months of study enrolment. Topical, intra-articularly injected, or inhaled glucocorticoids, topical calcineurin inhibitors or imiquimod are allowed. * Receipt of any immunoglobulins and/or any blood products within 9 months of study enrolment or planned administration of any of these products during the study period. * Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, even if stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports. * History of anemia. * Presence of a temperature ≥ 38.0ºC (≥100.4ºF), (oral temperature assessment preferred), or acute symptoms greater than mild severity on the scheduled date of first vaccination * Diagnosed with cancer, or treatment for cancer, within 3 years. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. (No laboratory testing is required.) * Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin outside of 24 hours prior to vaccination are eligible. Persons receiving prophylactic antiplatelet medications, e.g., low-dose acetylsalicylic acid, and without a clinically-apparent bleeding tendency, are eligible. * An acute evolving neurological disorder or history of Guillain-Barré syndrome within six weeks of receipt of any vaccine. * Any known or suspected allergy to any constituent of influenza vaccines (including egg proteins or mercurial preservatives); a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to any vaccine. * Known pregnancy or a positive urine beta-human chorionic gonadotropin (β-HCG) test result prior to first vaccination. * Lactating or nursing women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164). | Seroconversion rate (SCR) was defined as the number of subjects who have either a pre-vaccination reciprocal HI titer \< 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus. |
| Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164). | Seroprotection rate (SPR) was defined as the number of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus. |
| Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 122 to Day 164). | Geometric mean fold-rise (GMFR), or seronversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus. |
| Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164). | A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10. |
| Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164). | Titers were expressed as geometric mean antibody titers (GMTs). |
| Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164). | VRR for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. The cut-off value for microneutralization titers is 1:28. |
| Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164). | Seroconversion rate (SCR) was defined as the number of subjects who have either a pre-vaccination reciprocal HI titer \< 1:10 and a post-vaccination reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus. |
| Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164). | Seroprotection rate (SPR) was defined as the number of subjects with H1N1 reciprocal HI titers ≥ 1:40 against the tested vaccine virus. |
| Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 122 to Day 164). | Geometric mean fold-rise (GMFR), or seronversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus. |
| Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164). | A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10. |
| Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164). | Titers were expressed as geometric mean antibody titers (GMTs). |
| Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164). | VRR for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. The cut-off value for microneutralization titers is 1:28. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | During the 7-day (Days 0-6) follow-up period after vaccination. | Solicited local symptoms assessed were pain, redness and swelling and data collected was pooled by administration of vaccination received at Day 0 (i.e. Flulaval or Saline placebo). Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal activity. Grade 3 redness and swelling were defined as redness/swelling above 100 millimeter (mm). |
| Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | During the 7-day (Days 0-6) follow-up period after vaccination. | Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature (= axillary temperature equal to or above 38.0 degrees Celsius (°C)) and data collected was pooled by administration of vaccination received at Day 0 (i.e. Flulaval or Saline placebo). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = axillary temperature above 39.0°C. |
| Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | During the 7-day (Days 0-6) follow-up period after vaccination. | Solicited local symptoms assessed were pain, redness and swelling and were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal activity. Grade 3 redness and swelling were defined as redness/swelling above 100 millimeter (mm). |
| Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | At Day 122 and Day 304 | A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10. |
| Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | On Days 0, 21, 122 and 164 | Laboratory parameters assessed were white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), red blood cells (RBC), hemoglobin (Hgb), hematocrit (Hct) and platelets (PLA). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated). |
| Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | On Days 0, 21, 122 and 164 | Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatise (AP), creatinine (CREA), blood urea nitrogen (BUN) and bilirubin (BIL) (total (T) and direct (D)). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated). |
| Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | During the 7-day (Days 0-6) follow-up period after vaccination. | Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature (= axillary temperature equal to or above 38.0 degrees Celsius (°C)) and were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine. Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = axillary temperature above 39.0°C. |
| Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | At Days 122 and 304 | Titers were expressed as geometric mean antibody titers (GMTs). |
| Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | Entire study period up to Day 507 | VRR for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. The cut-off value for microneutralization titers is 1:28. |
| Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | At Days 0 and 304 | A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10. |
| Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | At Day 0 and Day 304 | Titers were expressed as geometric mean antibody titers (GMTs). |
| Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | For the entire study period up to Day 507 | VRR for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. The cut-off value for microneutralization titers is 1:28. |
| Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | Before administration of Arepanrix vaccine (Day 0 to Day 122) | CD4 T cell-mediated immune responses against the antigens A/California/7/2009, A/Brisbane/59/2007 and A/Uruguay/716/2007 were analyzed for cells expressing at least 2 of the following immune markers: CD40 Ligand, Interleukin-2, Tumor Necrosis Factor alpha or Interferon-gamma. The frequency was presented as number of cytokine-producing CD4+ cells per million CD4+ cells. All doubles= T cell expressing at least 2 cytokines. Subjects with missing results were not included. |
| Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | After the administration of Arepanrix vaccine (Day 125 to 304) | CD4 T cell-mediated immune responses against the antigens A/California/7/2009, A/Brisbane/59/2007 and A/Uruguay/716/2007 were analyzed for cells expressing at least 2 of the following immune markers: CD40 Ligand, Interleukin2, Tumor Necrosis Factor alpha or Interferongamma. The frequency was presented as number of cytokineproducing CD4+ cells per million CD4+ cells. All doubles= T cell expressing at least 2 cytokines. |
| Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | During the entire study period (up to Day 507). | pIMDs are a subset of adverse events (AEs) that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related = symptom assed by the investigator as causally related to the study vaccination. |
| Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | During the entire study period (up to Day 507). | MAEs refer to events that required medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Related = symptom assed by the investigator as causally related to the study vaccination. |
| Number of Subjects Reporting Unsolicited AEs. | Up to 21-day (Days 0-20) after vaccination | An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Unsolicited AEs were collected after the administration of the Flulaval vaccine or the placebo dose and the data has been pooled based on the vaccination received at Day 0. |
| Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | During the entire study period (up to Day 507). | SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. Related = symptom assed by the investigator as causally related to the study vaccination. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Flulaval/Arepanrix Group subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143. | 33 |
| Flulaval/Unadjuvanted Arepanrix Group subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143. | 34 |
| Placebo/Arepanrix Group subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143. | 33 |
| Placebo/Unadjuvanted Arepanrix Group subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143. | 33 |
| Total | 133 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Other | 7 | 1 | 8 | 6 |
Baseline characteristics
| Characteristic | Flulaval/Arepanrix Group | Flulaval/Unadjuvanted Arepanrix Group | Placebo/Arepanrix Group | Placebo/Unadjuvanted Arepanrix Group | Total |
|---|---|---|---|---|---|
| Age, Continuous | 29.6 Years STANDARD_DEVIATION 6.44 | 29.0 Years STANDARD_DEVIATION 7.05 | 28.6 Years STANDARD_DEVIATION 6.17 | 29.8 Years STANDARD_DEVIATION 7.24 | 29.3 Years STANDARD_DEVIATION 6.73 |
| Sex: Female, Male Female | 15 Participants | 19 Participants | 17 Participants | 21 Participants | 72 Participants |
| Sex: Female, Male Male | 18 Participants | 15 Participants | 16 Participants | 12 Participants | 61 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 24 / 33 | 25 / 34 | 27 / 33 | 17 / 33 | 44 / 67 | 19 / 66 |
| serious Total, serious adverse events | 3 / 33 | 1 / 34 | 1 / 33 | 1 / 33 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
Seroconversion rate (SCR) was defined as the number of subjects who have either a pre-vaccination reciprocal HI titer \< 1:10 and a post-vaccination reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.
Time frame: 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flulaval/Arepanrix Group | Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 16 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 18 Subjects |
| Placebo/Arepanrix Group | Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 6 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 2 Subjects |
Primary
Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
Seroconversion rate (SCR) was defined as the number of subjects who have either a pre-vaccination reciprocal HI titer \< 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.
Time frame: 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flulaval/Arepanrix Group | Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 21 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 28 Subjects |
| Placebo/Arepanrix Group | Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 25 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 26 Subjects |
Primary
Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.
Time frame: 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 21 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 33 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 24 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 27 Subjects |
Primary
Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.
Time frame: 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 21 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 33 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 25 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 27 Subjects |
Primary
Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
Seroprotection rate (SPR) was defined as the number of subjects with H1N1 reciprocal HI titers ≥ 1:40 against the tested vaccine virus.
Time frame: 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flulaval/Arepanrix Group | Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 20 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 30 Subjects |
| Placebo/Arepanrix Group | Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 18 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 14 Subjects |
Primary
Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
Seroprotection rate (SPR) was defined as the number of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.
Time frame: 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flulaval/Arepanrix Group | Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 21 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 33 Subjects |
| Placebo/Arepanrix Group | Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 25 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 27 Subjects |
Primary
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
Geometric mean fold-rise (GMFR), or seronversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.
Time frame: 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 122 to Day 164).
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Flulaval/Arepanrix Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 7.5 Fold increase |
| Flulaval/Unadjuvanted Arepanrix Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 4.7 Fold increase |
| Placebo/Arepanrix Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 2.6 Fold increase |
| Placebo/Unadjuvanted Arepanrix Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 1.9 Fold increase |
Primary
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
Geometric mean fold-rise (GMFR), or seronversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.
Time frame: 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 122 to Day 164).
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Flulaval/Arepanrix Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 40.3 Fold |
| Flulaval/Unadjuvanted Arepanrix Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 20.8 Fold |
| Placebo/Arepanrix Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 57.4 Fold |
| Placebo/Unadjuvanted Arepanrix Group | Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 25.8 Fold |
Primary
Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
Titers were expressed as geometric mean antibody titers (GMTs).
Time frame: 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 144.9 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 123.1 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 49.2 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 35.2 Titers |
Primary
Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
Titers were expressed as geometric mean antibody titers (GMTs).
Time frame: 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 650.7 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 259.4 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 799.0 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 332.7 Titers |
Primary
Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
VRR for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. The cut-off value for microneutralization titers is 1:28.
Time frame: 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flulaval/Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 17 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 18 Subjects |
| Placebo/Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 8 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 3 Subjects |
Primary
Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
VRR for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. The cut-off value for microneutralization titers is 1:28.
Time frame: 21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flulaval/Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 18 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 21 Subjects |
| Placebo/Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 24 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 20 Subjects |
Secondary
Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens
CD4 T cell-mediated immune responses against the antigens A/California/7/2009, A/Brisbane/59/2007 and A/Uruguay/716/2007 were analyzed for cells expressing at least 2 of the following immune markers: CD40 Ligand, Interleukin-2, Tumor Necrosis Factor alpha or Interferon-gamma. The frequency was presented as number of cytokine-producing CD4+ cells per million CD4+ cells. All doubles= T cell expressing at least 2 cytokines. Subjects with missing results were not included.
Time frame: Before administration of Arepanrix vaccine (Day 0 to Day 122)
Population: The ATP cohort for immunogenicity at Day 164 included subjects who received protocol specified vaccine(s) during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after second H1N1 vaccine dose (Day 164). Subjects with missing results were not included.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IFNg, Day 0 [N=41,41] | 1073.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 21 [N=41,43] | 1699.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IFNg, Day 7 [N=43,41] | 1460.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double CD40L, Day 7 [N=43,41] | 1337.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IFNg, Day 14 [N=44,42] | 1463.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 All doubles, Day 14 [N=44,43] | 1917.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IFNg, Day 21 [N=41,43] | 1361.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double CD40L, Day 14 [N=44,43] | 1734.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IFNg, Day 122 [N=40,42] | 1230.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 122 [N=40,42] | 1583.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IFNg, Day 0 [N=41,41] | 1158.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double CD40L, Day 21 [N=41,42] | 1336.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IFNg, Day 7 [N=42,40] | 1532.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles, Day 122 [N=41,42] | 1777.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IFNg, Day 14 [N=43,43] | 1790.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double CD40L, Day 122 [N=41,42] | 1355.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IFNg, Day 21 [N=41,43] | 1752.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles, Day 0 [N=41,41] | 1339.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IFNg, Day 122 [N=41,40] | 1222.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double CD40L, Day 0 [N=41,41] | 1134.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IL-2, Day 0 [N=41,41] | 1464.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 All doubles, Day 21 [N=41,42] | 1693.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IL-2, Day 7 [N=43,41] | 2089.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double CD40L, Day 7 [N=43,41] | 1521.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IL-2, Day 14 [N=44,43] | 2255.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles, Day 7 [N=42,40] | 1884.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IL-2, Day 21 [N=41,43] | 1991.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double CD40L, Day 14 [N=44,42] | 1585.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IL-2, Day 122 [N=41,42] | 1585.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles, Day 7 [N=43,41] | 2559.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IL-2, Day 0 [N=41,41] | 1103.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double CD40L, Day 21 [N=41,43] | 1504.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IL-2, Day 7 [N=43,41] | 1370.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles, Day 14 [N=43,43] | 2264.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IL-2, Day 14 [N=44,44] | 1590.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double CD40L, Day 122 [N=40,42] | 1402.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IL-2, Day 21 [N=41,42] | 1299.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 All doubles, Day 122 [N=41,42] | 1534.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IL-2, Day 122 [N=41,42] | 1252.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double CD40L, Day 0 [N=41,41] | 1283.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IL-2, Day 0 [N=41,41] | 1092.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles, Day 21 [N=41,43] | 2212.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IL-2, Day 7 [N=43,41] | 1375.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double CD40L, Day 7 [N=42,40] | 1598.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IL-2, Day 14 [N=44,42] | 1598.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 All doubles, Day 0 [N=41,41] | 1331.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IL-2, Day 21 [N=41,43] | 1406.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double CD40L, Day 14 [N=43,43] | 1952.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IL-2, Day 122 [N=40,42] | 1276.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles, Day 122 [N=41,40] | 1688.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IL-2, Day 0 [N=41,41] | 1191.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double CD40L, Day 21 [N=41,43] | 1955.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IL-2, Day 7 [N=42,40] | 1677.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 0 [N=41,41] | 1318.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IL-2, Day 14 [N=43,43] | 1879.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double CD40L, Day 122 [N=41,40] | 1494.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IL-2, Day 21 [N=41,43] | 1784.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L, Day 0 [N=41,41] | 1549.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IL-2, Day 122 [N=41,40] | 1378.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IFNg, Day 0 [N=41,41] | 1441.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double TNF-a, Day 0 [N=41,41] | 1339.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles, Day 21 [N=41,43] | 2496.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double TNF-a, Day 7 [N=43,41] | 1751.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IFNg, Day 7 [N=43,41] | 1964.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double TNF-a, Day 14 [N=44,43] | 1849.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L, Day 7 [N=43,41] | 2443.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double TNF-a, Day 21 [N=41,43] | 1474.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IFNg, Day 14 [N=44,43] | 2148.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double TNF-a, Day 122 [N=41,42] | 1281.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 7 [N=43,41] | 1751.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double TNF-a, Day 0 [N=41,41] | 1015.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IFNg, Day 21 [N=41,43] | 1973.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double TNF-a, Day 7 [N=43,41] | 1245.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L, Day 14 [N=44,43] | 2323.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double TNF-a, Day 14 [N=44,43] | 1338.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IFNg, Day 122 [N=41,42] | 1535.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double TNF-a, Day 21 [N=41,42] | 1209.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 All doubles, Day 7 [N=43,41] | 1746.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double TNF-a, Day 122 [N=42,41] | 1016.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IFNg, Day 0 [N=41,41] | 913.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double TNF-a, Day 0 [N=41,41] | 920.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L, Day 21 [N=41,43] | 2187.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double TNF-a, Day 7 [N=43,41] | 1186.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IFNg, Day 7 [N=43,41] | 1307.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double TNF-a, Day 14 [N=44,43] | 1104.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 14 [N=44,42] | 1807.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double TNF-a, Day 21 [N=41,43] | 1133.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IFNg, Day 14 [N=44,43] | 1453.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double TNF-a, Day 122 [N=40,42] | 1104.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L, Day 122 [N=41,42] | 1735.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double TNF-a, Day 0 [N=41,41] | 986.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IFNg, Day 21 [N=41,42] | 1398.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double TNF-a, Day 7 [N=42,40] | 1093.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles, Day 14 [N=44,43] | 2648.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double TNF-a, Day 14 [N=43,43] | 1408.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IFNg, Day 122 [N=41,42] | 1019.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double TNF-a, Day 21 [N=41,43] | 1275.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double CD40L, Day 0 [N=41,41] | 1070.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double TNF-a, Day 122 [N=41,40] | 1020.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles, Day 0 [N=41,41] | 1699.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double TNF-a, Day 122 [N=41,40] | 748.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles, Day 0 [N=41,41] | 1622.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles, Day 7 [N=43,41] | 1649.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles, Day 14 [N=44,43] | 1553.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles, Day 21 [N=41,43] | 1599.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles, Day 122 [N=41,42] | 1600.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 All doubles, Day 0 [N=41,41] | 1073.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 All doubles, Day 7 [N=43,41] | 1209.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 All doubles, Day 14 [N=44,43] | 1133.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 All doubles, Day 21 [N=41,42] | 1267.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 All doubles, Day 122 [N=41,42] | 970.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 0 [N=41,41] | 1131.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 7 [N=43,41] | 1292.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 14 [N=44,42] | 1093.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 21 [N=41,43] | 1245.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 122 [N=40,42] | 1196.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles, Day 0 [N=41,41] | 1317.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles, Day 7 [N=42,40] | 1764.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles, Day 14 [N=43,43] | 1567.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles, Day 21 [N=41,43] | 1520.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles, Day 122 [N=41,40] | 1150.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L, Day 0 [N=41,41] | 1394.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L, Day 7 [N=43,41] | 1457.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L, Day 14 [N=44,43] | 1369.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L, Day 21 [N=41,43] | 1453.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L, Day 122 [N=41,42] | 1404.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double CD40L, Day 0 [N=41,41] | 942.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double CD40L, Day 7 [N=43,41] | 1077.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double CD40L, Day 14 [N=44,43] | 936.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double CD40L, Day 21 [N=41,42] | 1010.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double CD40L, Day 122 [N=41,42] | 846.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double CD40L, Day 0 [N=41,41] | 1076.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double CD40L, Day 7 [N=43,41] | 1076.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double CD40L, Day 14 [N=44,42] | 809.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double CD40L, Day 21 [N=41,43] | 1060.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double CD40L, Day 122 [N=40,42] | 1033.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double CD40L, Day 0 [N=41,41] | 1135.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double CD40L, Day 7 [N=42,40] | 1436.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double CD40L, Day 14 [N=43,43] | 1356.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double CD40L, Day 21 [N=41,43] | 1296.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double CD40L, Day 122 [N=41,40] | 1051.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IFNg, Day 0 [N=41,41] | 1161.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IFNg, Day 7 [N=43,41] | 1231.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IFNg, Day 14 [N=44,43] | 1196.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IFNg, Day 21 [N=41,43] | 1121.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IFNg, Day 122 [N=41,42] | 1181.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IFNg, Day 0 [N=41,41] | 823.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IFNg, Day 7 [N=43,41] | 1000.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IFNg, Day 14 [N=44,43] | 808.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IFNg, Day 21 [N=41,42] | 943.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IFNg, Day 122 [N=41,42] | 910.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IFNg, Day 0 [N=41,41] | 962.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IFNg, Day 7 [N=43,41] | 1027.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IFNg, Day 14 [N=44,42] | 842.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IFNg, Day 21 [N=41,43] | 1005.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IFNg, Day 122 [N=40,42] | 1009.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IFNg, Day 0 [N=41,41] | 1124.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IFNg, Day 7 [N=42,40] | 1406.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IFNg, Day 14 [N=43,43] | 1281.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IFNg, Day 21 [N=41,43] | 1262.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IFNg, Day 122 [N=41,40] | 1109.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IL-2, Day 0 [N=41,41] | 1220.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IL-2, Day 7 [N=43,41] | 1347.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IL-2, Day 14 [N=44,43] | 1284.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IL-2, Day 21 [N=41,43] | 1427.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double IL-2, Day 122 [N=41,42] | 1323.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IL-2, Day 0 [N=41,41] | 855.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IL-2, Day 7 [N=43,41] | 1001.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IL-2, Day 14 [N=44,44] | 1010.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IL-2, Day 21 [N=41,42] | 1061.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double IL-2, Day 122 [N=41,42] | 835.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IL-2, Day 0 [N=41,41] | 939.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IL-2, Day 7 [N=43,41] | 1116.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IL-2, Day 14 [N=44,42] | 975.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IL-2, Day 21 [N=41,43] | 1168.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double IL-2, Day 122 [N=40,42] | 1049.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IL-2, Day 0 [N=41,41] | 1110.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IL-2, Day 7 [N=42,40] | 1442.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IL-2, Day 14 [N=43,43] | 1242.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IL-2, Day 21 [N=41,43] | 1336.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double IL-2, Day 122 [N=41,40] | 961.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double TNF-a, Day 0 [N=41,41] | 1153.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double TNF-a, Day 7 [N=43,41] | 1201.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double TNF-a, Day 14 [N=44,43] | 1032.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double TNF-a, Day 21 [N=41,43] | 1142.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double TNF-a, Day 122 [N=41,42] | 1153.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double TNF-a, Day 0 [N=41,41] | 867.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double TNF-a, Day 7 [N=43,41] | 976.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double TNF-a, Day 14 [N=44,43] | 816.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double TNF-a, Day 21 [N=41,42] | 936.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California, CD4 Double TNF-a, Day 122 [N=42,41] | 651.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double TNF-a, Day 0 [N=41,41] | 786.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double TNF-a, Day 7 [N=43,41] | 986.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double TNF-a, Day 14 [N=44,43] | 756.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double TNF-a, Day 21 [N=41,43] | 909.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 Double TNF-a, Day 122 [N=40,42] | 849.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double TNF-a, Day 0 [N=41,41] | 875.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double TNF-a, Day 7 [N=42,40] | 1037.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double TNF-a, Day 14 [N=43,43] | 970.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of T-cell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 Double TNF-a, Day 21 [N=41,43] | 900.0 cells/million T cells |
Secondary
Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens
CD4 T cell-mediated immune responses against the antigens A/California/7/2009, A/Brisbane/59/2007 and A/Uruguay/716/2007 were analyzed for cells expressing at least 2 of the following immune markers: CD40 Ligand, Interleukin2, Tumor Necrosis Factor alpha or Interferongamma. The frequency was presented as number of cytokineproducing CD4+ cells per million CD4+ cells. All doubles= T cell expressing at least 2 cytokines.
Time frame: After the administration of Arepanrix vaccine (Day 125 to 304)
Population: The According-To-Protocol cohort for immunogenicity at Day 304 included all evaluable subjects who had not received a vaccine not specified or forbidden in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen for the blood sample taken at Day 304.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day150[N=16,22,23,21] | 2168.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 136[N=18,24,20,22 | 2340.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 150[N=16,21,23,22] | 1294.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 143[N=16,27,20,18] | 887.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day157[N=17,22,20,18] | 2314.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 136 [N=18,24,20,22] | 1429.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 136[N=18,24,20,22] | 1140.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 129[N=17,26,21,22] | 814.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day164[N=16,19,19,21] | 2162.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 136[N=18,24,20,22] | 1944.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 125[N=14,21,16,17] | 886.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 304[N=18,28,19,27] | 1250.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day304[N=18,28,19,27] | 1441.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 129[N=17,25,23,22] | 1482.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 164[N=16,19,19,21] | 1692.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 157[N=17,22,20,18] | 2109.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 143[N=17,27,20,18 | 1893.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 150[N=16,26,23,21] | 1937.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 143[N=17,27,20,18] | 1169.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 129 [N=17,26,21,22] | 1189.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 129 [N=17,26,21,22] | 1067.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 136[N=18,24,20,22] | 1621.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 129[N=17,26,23,22] | 1044.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 136 [N=18,24,20,22] | 1438.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 125[N=14,22,16,17] | 1293.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 125[N=14,21,15,17] | 754.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 304 [N=18,28,19,27] | 1257.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 143 [N=16,27,20,18] | 1359.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 304[N=18,28,19,27] | 1790.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 164 [N=16,20,19,21] | 1813.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 157 [N=17,22,20,18] | 2529.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 150 [N=16,21,23,22] | 1575.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 150[N=16,22,23,21 | 2549.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 150 [N=16,22,23,22] | 1761.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 143 [N=17,27,20,18] | 1520.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 157 [N=17,21,20,18] | 1691.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 143[N=17,27,20,18] | 2330.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 136 [N=18,24,20,22] | 1769.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 129 [N=17,25,23,22] | 1257.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 164 [N=16,19,19,21] | 1545.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 164[N=16,19,19,21] | 1564.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 125 [N=14,22,16,17] | 993.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 304 [N=18,28,19,27] | 1578.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 304 [N=18,28,19,27] | 1392.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 157[N=17,22,20,18] | 1700.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 164 [N=16,19,19,21] | 1478.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 157 [N=17,22,20,18] | 1611.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 125 [N=14,22,16,17] | 1201.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 157[N=17,22,20,18 | 2685.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 150 [N=16,20,23,22] | 1541.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 143 [N=16,27,20,18] | 1280.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 129 [N=17,24,23,22] | 1379.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 129[N=17,25,23,22] | 1750.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 136 [N=18,25,19,22] | 1847.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 150[N=16,20,23,22] | 1697.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 143[N=16,27,20,18] | 1348.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 164[N=16,19,19,21 | 2590.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 125 [N=14,21,16,17] | 798.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 136[N=18,25,19,22] | 1966.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 129[N=17,24,23,22] | 1555.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 304[N=18,28,19,27 | 1616.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 304[N=18,28,19,27] | 1105.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 125[N=14,22,16,17] | 1302.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 304 [N=18,28,19,27] | 1551.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 125[N=14,21,16,17] | 1237.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 150[N=16,22,23,22] | 2690.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 164 [N=16,19,19,21] | 1663.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 157 [N=17,21,20,18] | 1796.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 129[N=17,26,21,22] | 1381.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 164 [N=16,19,19,21] | 1476.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 150 [N=16,21,23,22] | 1752.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 143 [N=16,27,20,18] | 1465.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 136[N=18,24,20,22] | 1791.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 164[N=16,19,19,21] | 1715.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 136 [N=18,24,20,22] | 1596.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 304 [N=18,28,19,27] | 1281.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 157[N=17,22,20,18] | 1771.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 129 [N=17,26,21,22] | 1303.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 125 [N=14,21,16,17] | 1115.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 125 [N=14,22,16,17] | 1050.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 157[N=17,22,20,18] | 3136.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day304[N=18,28,19,27 | 1537.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day164[N=16,19,19,21 | 2057.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 129 [N=17,24,23,22] | 1391.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 150 [N=16,21,23,22] | 1473.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day157[N=17,22,20,18 | 2276.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day150[N=16,22,23,21 | 2278.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 136 [N=18,25,19,22] | 1694.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 150[N=16,23,22,21] | 1828.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day143[N=17,27,20,18 | 1613.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day136[N=18,24,20,22 | 1921.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 143 [N=16,27,20,18] | 1311.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 143[N=17,27,20,18] | 1267.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day129[N=17,26,23,22 | 1166.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day125[N=14,21,15,17 | 972.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 150 [N=16,20,22,23] | 1410.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 164[N=16,20,19,21] | 2906.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day304[N=18,28,19,27] | 1889.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day164[N=16,20,19,21] | 2518.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 157 [N=17,22,20,18] | 1397.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 143 [N=16,27,20,18] | 1395.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day157[N=17,22,20,18] | 2913.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day150[N=16,22,23,22] | 2217.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 164 [N=16,19,19,21] | 1477.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 136[N=18,24,23,22] | 1548.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day143[N=17,27,20,18] | 2178.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day136[N=18,24,20,22] | 2263.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 304 [N=18,28,19,27] | 1471.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 129[N=17,26,23,22] | 1155.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 125 [N=14,21,16,17] | 916.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day129[N=17,25,23,22] | 1525.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day125[N=14,22,16,17] | 1489.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 125 [N=14,22,16,17] | 1229.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 304[N=18,28,19,27] | 2041.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 304[N=18,28,19,27] | 1837.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 164[N=16,19,19,22] | 1734.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 129 [N=17,25,23,22] | 1331.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 136[N=14,22,16,17] | 2683.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 157[N=17,22,20,18] | 1945.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 150[N=16,20,23,22] | 1851.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 136 [N=18,24,20,22] | 2051.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 125[N=14,22,16,17] | 753.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 143[N=16,27,20,18] | 1596.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 136[N=18,25,19,22] | 2205.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 143 [N=17,27,20,18] | 1922.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 304[N=18,28,19,27] | 1748.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 125[N=14,22,16,17] | 1582.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 125[N=14,22,16,17] | 1416.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 150 [N=16,22,23,22] | 2189.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 125[N=14,21,15,17 | 1066.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 304[N=18,28,19,27] | 1662.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 164[N=16,19,19,21] | 1870.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 157 [N=17,22,20,18] | 2407.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 129[N=17,24,23,22] | 1706.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 157[N=17,21,20,18] | 1924.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 150[N=16,21,23,22] | 1921.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 164 [N=16,20,19,21] | 2561.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 164[N=16,20,19,21] | 2208.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 143[N=16,27,20,18] | 1661.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 304[N=18,28,19,27] | 1258.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 304 [N=18,28,19,27] | 1665.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 157[N=17,22,20,18] | 2247.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 164[N=16,19,19,21] | 1130.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 157[N=17,22,20,18] | 1041.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day125[N=14,21,15,17] | 882.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 129[N=17,26,23,22 | 1458.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 150[N=16,20,23,22] | 1175.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 143[N=16,27,20,18] | 1015.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day129[N=17,26,23,22] | 1209.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 157 [N=17,21,20,22] | 1709.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 136[N=18,25,19,22] | 1250.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 129[N=17,24,23,22] | 955.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day136[N=18,24,20,22] | 2064.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 150[N=16,22,23,22] | 2150.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 125[N=14,22,16,17] | 922.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 304[N=18,28,19,27] | 1136.5 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day143[N=17,27,20,18] | 1572.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 143[N=17,27,20,18] | 1630.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 164[N=16,19,19,21] | 1358.0 cells/million T cells |
| Flulaval/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 157[N=17,21,20,18] | 1492.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 125 [N=14,22,16,17] | 1022.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 129[N=17,25,23,22] | 2099.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 136[N=14,22,16,17] | 2288.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 143[N=17,27,20,18] | 2393.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 150[N=16,22,23,22] | 2380.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 157[N=17,22,20,18] | 2178.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 164[N=16,20,19,21] | 2316.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 304[N=18,28,19,27] | 1945.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 125[N=14,21,15,17 | 1097.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 129[N=17,26,23,22 | 1576.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 136[N=18,24,20,22 | 1779.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 143[N=17,27,20,18 | 1735.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 150[N=16,22,23,21 | 1918.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 157[N=17,22,20,18 | 1760.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 164[N=16,19,19,21 | 1692.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 304[N=18,28,19,27 | 1392.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 125[N=14,21,16,17] | 998.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 129[N=17,26,21,22] | 1215.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 136[N=18,24,20,22] | 1576.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 304 [N=18,28,19,27] | 1113.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 125[N=14,22,16,17] | 1652.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 129 [N=17,24,23,22] | 1178.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 136 [N=18,25,19,22] | 1253.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 143 [N=16,27,20,18] | 1293.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 150 [N=16,20,22,23] | 1359.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 157 [N=17,22,20,18] | 1417.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 164 [N=16,19,19,21] | 1166.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 304 [N=18,28,19,27] | 1337.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 125 [N=14,22,16,17] | 1343.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 129 [N=17,25,23,22] | 1844.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 136 [N=18,24,20,22] | 1933.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 143 [N=17,27,20,18] | 2045.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 150 [N=16,22,23,22] | 1891.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 157 [N=17,22,20,18] | 1816.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 164 [N=16,20,19,21] | 1956.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 304 [N=18,28,19,27] | 1592.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day125[N=14,21,15,17] | 986.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day129[N=17,26,23,22] | 1206.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day136[N=18,24,20,22] | 1496.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day143[N=17,27,20,18] | 1538.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day150[N=16,22,23,21] | 1645.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day157[N=17,22,20,18] | 1559.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day164[N=16,19,19,21] | 1581.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day304[N=18,28,19,27] | 1272.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 125 [N=14,21,16,17] | 840.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 129 [N=17,26,21,22] | 1037.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 136 [N=18,24,20,22] | 1322.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 143 [N=16,27,20,18] | 1255.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 150 [N=16,21,23,22] | 1158.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 157 [N=17,21,20,18] | 1249.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 164 [N=16,19,19,21] | 1029.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 304 [N=18,28,19,27] | 1317.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 125 [N=14,22,16,17] | 1089.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 129 [N=17,24,23,22] | 1257.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 136 [N=18,25,19,22] | 1290.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 143 [N=16,27,20,18] | 1381.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 150 [N=16,20,23,22] | 1365.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 157 [N=17,22,20,18] | 1299.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 164 [N=16,19,19,21] | 1191.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 304 [N=18,28,19,27] | 1374.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 125 [N=14,22,16,17] | 1089.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 129 [N=17,25,23,22] | 1313.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 136 [N=18,24,20,22] | 1575.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 143 [N=17,27,20,18] | 1659.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 150 [N=16,22,23,22] | 1549.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 157 [N=17,22,20,18] | 1485.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 164 [N=16,20,19,21] | 1476.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 304 [N=18,28,19,27] | 1357.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 125[N=14,21,15,17] | 777.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 129[N=17,26,23,22] | 1129.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 136[N=18,24,20,22] | 1279.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 143[N=17,27,20,18] | 1104.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 150[N=16,26,23,21] | 1293.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 157[N=17,22,20,18] | 1243.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 164[N=16,19,19,21] | 1074.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 304[N=18,28,19,27] | 1063.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 125[N=14,21,16,17] | 724.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 129[N=17,26,21,22] | 757.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 136[N=18,24,20,22] | 995.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 143[N=16,27,20,18] | 973.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 150[N=16,21,23,22] | 873.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 157[N=17,21,20,18] | 947.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 164[N=16,19,19,21] | 900.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 304[N=18,28,19,27] | 1078.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 125[N=14,22,16,17] | 775.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 129[N=17,24,23,22] | 869.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 136[N=18,25,19,22] | 802.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 143[N=16,27,20,18] | 961.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 150[N=16,20,23,22] | 1044.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 157[N=17,22,20,18] | 965.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 164[N=16,19,19,21] | 866.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 304[N=18,28,19,27] | 1036.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 143[N=16,27,20,18] | 1566.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 150[N=16,21,23,22] | 1391.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 157[N=17,21,20,18] | 1468.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 164[N=16,19,19,21] | 1287.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 304[N=18,28,19,27] | 1524.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 125[N=14,22,16,17] | 1310.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 129[N=17,24,23,22] | 1429.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 136[N=18,25,19,22] | 1484.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 143[N=16,27,20,18] | 1665.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 150[N=16,20,23,22] | 1612.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 157[N=17,22,20,18] | 1646.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 164[N=16,19,19,22] | 1422.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 304[N=18,28,19,27] | 1751.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day125[N=14,22,16,17] | 1627.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day129[N=17,25,23,22] | 2009.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day136[N=18,24,20,22] | 2049.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day143[N=17,27,20,18] | 2123.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day150[N=16,22,23,22] | 2059.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day157[N=17,22,20,18] | 1943.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day164[N=16,20,19,21] | 2125.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day304[N=18,28,19,27] | 1843.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day125[N=14,21,15,17 | 900.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day129[N=17,26,23,22 | 1376.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day136[N=18,24,20,22 | 1486.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day143[N=17,27,20,18 | 1626.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day150[N=16,22,23,21 | 1547.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day157[N=17,22,20,18 | 1544.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day164[N=16,19,19,21 | 1553.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day304[N=18,28,19,27 | 1329.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 125 [N=14,21,16,17] | 1040.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 129 [N=17,26,21,22] | 1075.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 136 [N=18,24,20,22] | 1426.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 143 [N=16,27,20,18] | 1454.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 150 [N=16,21,23,22] | 1214.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 157 [N=17,21,20,18] | 1321.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 164 [N=16,19,19,21] | 1250.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 304 [N=18,28,19,27] | 1440.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 125[N=14,22,16,17] | 1221.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 129[N=17,24,23,22] | 1336.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 136[N=18,25,19,22] | 1372.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 143[N=16,27,20,18] | 1511.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 150[N=16,20,23,22] | 1342.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 157[N=17,22,20,18] | 1497.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 164[N=16,19,19,21] | 1306.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 304[N=18,28,19,27] | 1616.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 125[N=14,22,16,17] | 1273.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 129[N=17,25,23,22] | 1606.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 136[N=18,24,20,22] | 1791.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 143[N=17,27,20,18] | 1833.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 150[N=16,22,23,22] | 1801.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 157[N=17,22,20,18] | 1809.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 164[N=16,20,19,21] | 1617.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 304[N=18,28,19,27] | 1551.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 125[N=14,22,16,17] | 832.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 129[N=17,26,23,22] | 1100.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 136[N=18,24,23,22] | 1321.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 143[N=17,27,20,18] | 1188.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 150[N=16,23,22,21] | 1417.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 157[N=17,22,20,18] | 1265.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 164[N=16,19,19,21] | 1320.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 304[N=18,28,19,27] | 1129.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 125 [N=14,21,16,17] | 791.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 129 [N=17,26,21,22] | 1012.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 136 [N=18,24,20,22] | 1142.5 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 143 [N=16,27,20,18] | 1216.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 150 [N=16,21,23,22] | 1234.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 157 [N=17,21,20,22] | 1220.0 cells/million T cells |
| Flulaval/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 164 [N=16,19,19,21] | 1105.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day150[N=16,22,23,21] | 2915.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 150[N=16,21,23,22] | 1333.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 136[N=14,22,16,17] | 2546.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 157[N=17,21,20,18] | 1398.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day143[N=17,27,20,18] | 2217.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 143[N=17,27,20,18] | 1899.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 164[N=16,19,19,21] | 1568.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 304[N=18,28,19,27] | 944.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day136[N=18,24,20,22] | 2284.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 129[N=17,26,23,22 | 1765.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 125[N=14,22,16,17] | 953.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 129[N=17,24,23,22] | 1077.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day129[N=17,26,23,22] | 1506.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 150[N=16,22,23,22] | 2335.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 136[N=18,25,19,22] | 1054.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 143[N=16,27,20,18] | 1189.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day125[N=14,21,15,17] | 925.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 150[N=16,20,23,22] | 849.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 136 [N=18,24,20,22] | 1390.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 157[N=17,22,20,18] | 1156.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 304 [N=18,28,19,27] | 1884.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 157[N=17,22,20,18] | 2234.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 164[N=16,19,19,21] | 1282.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 304[N=18,28,19,27] | 1042.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 164 [N=16,20,19,21] | 2536.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 125[N=14,21,15,17 | 1146.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 143[N=16,27,20,18] | 1999.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 150[N=16,21,23,22] | 2156.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 157 [N=17,22,20,18] | 2512.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 164[N=16,20,19,21] | 2446.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 157[N=17,21,20,18] | 1836.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 164[N=16,19,19,21] | 2167.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 150 [N=16,22,23,22] | 2771.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 304[N=18,28,19,27] | 1340.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 125[N=14,22,16,17] | 1574.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 143 [N=17,27,20,18] | 2246.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 304[N=18,28,19,27] | 1531.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 129[N=17,24,23,22] | 1491.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 136[N=18,25,19,22] | 1502.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 136 [N=18,24,20,22] | 2153.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 304[N=18,28,19,27] | 2115.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 143[N=16,27,20,18] | 1499.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 125[N=14,22,16,17] | 1332.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 150[N=16,20,23,22] | 1448.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 129 [N=17,25,23,22] | 1697.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 125[N=14,22,16,17] | 735.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 157[N=17,22,20,18] | 1951.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 164[N=16,19,19,22] | 2075.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 125 [N=14,22,16,17] | 1099.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 304[N=18,28,19,27] | 1398.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 143 [N=16,27,20,18] | 1575.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day125[N=14,22,16,17] | 1220.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 304 [N=18,28,19,27] | 1189.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 129[N=17,26,23,22] | 1469.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day129[N=17,25,23,22] | 1788.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day136[N=18,24,20,22] | 2292.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 164 [N=16,19,19,21] | 1540.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 164[N=16,20,19,21] | 2971.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day143[N=17,27,20,18] | 2322.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day150[N=16,22,23,22] | 2734.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 157 [N=17,22,20,18] | 1514.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 136[N=18,24,23,22] | 1752.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day157[N=17,22,20,18] | 2422.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day164[N=16,20,19,21] | 2579.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 150 [N=16,20,22,23] | 1362.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day304[N=18,28,19,27] | 1989.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 129[N=17,25,23,22] | 1950.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day125[N=14,21,15,17 | 948.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 143 [N=16,27,20,18] | 1205.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 143[N=17,27,20,18] | 1583.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day129[N=17,26,23,22 | 1438.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day136[N=18,24,20,22 | 2323.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 136 [N=18,25,19,22] | 1248.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 157[N=17,22,20,18] | 2981.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day143[N=17,27,20,18 | 2264.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day150[N=16,22,23,21 | 2995.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 129 [N=17,24,23,22] | 1308.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 150[N=16,23,22,21] | 2118.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day157[N=17,22,20,18 | 2662.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day164[N=16,19,19,21 | 2443.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 125 [N=14,22,16,17] | 1377.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day304[N=18,28,19,27 | 1770.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 150 [N=16,21,23,22] | 1561.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 125 [N=14,21,16,17] | 845.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 304 [N=18,28,19,27] | 1015.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 157[N=17,22,20,18] | 2080.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 129 [N=17,26,21,22] | 1096.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 136[N=18,24,20,22] | 1738.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 136 [N=18,24,20,22] | 1546.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 150[N=16,22,23,22] | 3272.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 143 [N=16,27,20,18] | 1753.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 129[N=17,26,21,22] | 1239.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 150 [N=16,21,23,22] | 1800.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 164[N=16,19,19,21] | 2444.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 157 [N=17,21,20,18] | 1662.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 125[N=14,21,16,17] | 1094.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 164 [N=16,19,19,21] | 1780.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 304 [N=18,28,19,27] | 1267.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 304[N=18,28,19,27 | 2138.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 125[N=14,22,16,17] | 1299.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 304[N=18,28,19,27] | 1351.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 129[N=17,24,23,22] | 1106.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 164[N=16,19,19,21 | 3168.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 136[N=18,25,19,22] | 1433.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 143[N=17,27,20,18] | 2535.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 143[N=16,27,20,18] | 1399.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 157[N=17,22,20,18 | 2971.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 164 [N=16,19,19,21] | 1688.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 129 [N=17,24,23,22] | 1238.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 150[N=16,20,23,22] | 1358.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 136 [N=18,25,19,22] | 1312.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 143 [N=16,27,20,18] | 1280.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 125 [N=14,22,16,17] | 1325.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 150 [N=16,20,23,22] | 1172.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 125 [N=14,21,16,17] | 965.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 157 [N=17,22,20,18] | 1587.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 304 [N=18,28,19,27] | 1165.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 157[N=17,22,20,18] | 1565.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 164 [N=16,19,19,21] | 1597.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 304 [N=18,28,19,27] | 1134.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 164 [N=16,19,19,21] | 1896.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 150[N=16,22,23,21 | 3308.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 125 [N=14,22,16,17] | 962.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 129 [N=17,25,23,22] | 1235.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 157 [N=17,21,20,18] | 1502.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 164[N=16,19,19,21] | 1751.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 136 [N=18,24,20,22] | 1869.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 143 [N=17,27,20,18] | 1672.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 150 [N=16,21,23,22] | 1739.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 150 [N=16,22,23,22] | 2260.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 157 [N=17,22,20,18] | 2082.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 143 [N=16,27,20,18] | 1642.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 304[N=18,28,19,27] | 1305.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 164 [N=16,20,19,21] | 2372.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 304 [N=18,28,19,27] | 1396.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 136 [N=18,24,20,22] | 1353.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 143[N=17,27,20,18 | 2544.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 125[N=14,21,15,17] | 847.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 157 [N=17,21,20,22] | 1435.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 129[N=17,26,23,22] | 1074.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 129 [N=17,26,21,22] | 1100.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 125[N=14,22,16,17] | 975.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 136[N=18,24,20,22] | 1594.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 143[N=17,27,20,18] | 1824.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 125 [N=14,21,16,17] | 900.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 150[N=16,26,23,21] | 1967.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 129 [N=17,26,21,22] | 1061.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 157[N=17,22,20,18] | 2244.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day304[N=18,28,19,27] | 1778.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 129[N=17,25,23,22] | 1497.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 164[N=16,19,19,21] | 2334.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 304[N=18,28,19,27] | 1581.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day164[N=16,19,19,21] | 2806.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 136[N=18,24,20,22 | 2550.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 125[N=14,21,16,17] | 763.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 129[N=17,26,21,22] | 878.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day157[N=17,22,20,18] | 2485.0 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 136[N=18,24,20,22] | 2037.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 136[N=18,24,20,22] | 1215.5 cells/million T cells |
| Placebo/Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 143[N=16,27,20,18] | 1492.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 304[N=18,28,19,27] | 1027.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 150[N=16,22,23,22] | 2200.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 150[N=16,21,23,22] | 836.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day143[N=17,27,20,18] | 1500.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 136[N=18,24,20,22] | 1260.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day304[N=18,28,19,27 | 1144.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 157[N=17,21,20,18] | 989.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 304 [N=18,28,19,27] | 1089.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 125 [N=14,22,16,17] | 859.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 157 [N=17,21,20,18] | 1199.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 164[N=16,19,19,21] | 888.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day136[N=18,24,20,22] | 1558.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 143[N=17,27,20,18] | 1639.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 125 [N=14,21,16,17] | 963.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 304[N=18,28,19,27] | 960.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 125 [N=14,21,16,17] | 882.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 125 [N=14,21,16,17] | 851.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 129 [N=17,25,23,22] | 1060.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 125[N=14,22,16,17] | 690.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day129[N=17,26,23,22] | 1144.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 157 [N=17,21,20,22] | 1088.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 129 [N=17,26,21,22] | 1069.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 129[N=17,24,23,22] | 708.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 125[N=14,22,16,17] | 884.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 157[N=17,22,20,18] | 1101.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 129[N=17,26,23,22 | 1457.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 136[N=18,25,19,22] | 774.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day125[N=14,21,15,17] | 937.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 150[N=16,22,23,22] | 1815.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 136 [N=18,24,20,22] | 1401.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 143[N=16,27,20,18] | 906.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 129[N=17,26,21,22] | 1176.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 125[N=14,21,15,17 | 1115.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 143[N=17,27,20,18] | 1241.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 150[N=16,20,23,22] | 731.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 304 [N=18,28,19,27] | 1460.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 136 [N=18,24,20,22] | 1288.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 143 [N=16,27,20,18] | 1175.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 157[N=17,22,20,18] | 830.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 150 [N=16,21,23,22] | 1063.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 150 [N=16,21,23,22] | 1104.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 164[N=16,19,19,21] | 1005.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 164[N=16,19,19,21] | 849.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 164 [N=16,20,19,21] | 1546.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 157[N=17,22,20,18] | 1774.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 150 [N=16,21,23,22] | 1250.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4Double TNFa,Day 304[N=18,28,19,27] | 1133.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 136[N=18,24,20,22] | 1555.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 125[N=14,21,16,17] | 990.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 143[N=16,27,20,18] | 938.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 143 [N=17,27,20,18] | 1404.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 143[N=16,27,20,18] | 1425.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 157 [N=17,22,20,18] | 1968.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 136 [N=18,24,20,22] | 1198.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 157 [N=17,21,20,18] | 1190.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 150[N=16,21,23,22] | 1308.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 136[N=18,24,20,22 | 1831.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 164[N=16,19,19,21] | 1031.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 143[N=17,27,20,18 | 1828.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 157[N=17,21,20,18] | 1510.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 150 [N=16,22,23,22] | 1908.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 164[N=16,20,19,21] | 1292.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 164 [N=16,19,19,21] | 1083.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 164[N=16,19,19,21] | 1251.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 304[N=18,28,19,27 | 1358.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 304[N=18,28,19,27] | 1797.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 143[N=17,27,20,18] | 2310.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay, CD4 All doubles, Day 304[N=18,28,19,27] | 1226.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 143 [N=17,27,20,18] | 1891.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 129[N=17,25,23,22] | 1907.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 136[N=18,24,20,22] | 991.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 125[N=14,22,16,17] | 993.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double CD40L,Day 304 [N=18,28,19,27] | 1131.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 150 [N=16,22,23,22] | 1325.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 125[N=14,22,16,17] | 1252.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 129[N=17,24,23,22] | 1103.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 136 [N=18,24,20,22] | 2009.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 304[N=18,28,19,27] | 1301.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 143 [N=16,27,20,18] | 1252.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 136[N=18,25,19,22] | 1130.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 125[N=14,22,16,17] | 877.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 164[N=16,19,19,21 | 1409.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 136[N=14,22,16,17] | 2289.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 143[N=16,27,20,18] | 1351.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 129 [N=17,25,23,22] | 1629.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 150[N=16,26,23,21] | 989.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 129[N=17,24,23,22] | 962.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 150[N=16,20,23,22] | 1324.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 157 [N=17,22,20,18] | 1392.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 304[N=18,28,19,27] | 1107.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day304[N=18,28,19,27] | 1208.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 157[N=17,22,20,18] | 1334.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IL-2,Day 125 [N=14,22,16,17] | 1038.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 125[N=14,22,16,17] | 748.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 136[N=18,25,19,22] | 1096.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 164[N=16,19,19,22] | 1272.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 157[N=17,22,20,18 | 1425.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 164[N=16,20,19,21] | 1838.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 125[N=14,21,16,17] | 620.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane, CD4 All doubles,Day 304[N=18,28,19,27] | 1602.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 304 [N=18,28,19,27] | 1398.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day157[N=17,22,20,18] | 1337.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 143[N=16,27,20,18] | 1153.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day125[N=14,22,16,17] | 1174.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 164 [N=16,20,19,21] | 1278.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 136 [N=18,24,20,22] | 1290.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 129 [N=17,24,23,22] | 1055.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day129[N=17,25,23,22] | 1772.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 164 [N=16,19,19,21] | 1088.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 129[N=17,26,23,22] | 1147.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 304[N=18,28,19,27] | 1599.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day136[N=18,24,20,22] | 2071.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 157[N=17,22,20,18] | 1004.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double TNFa,Day 304 [N=18,28,19,27] | 1169.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 136 [N=18,25,19,22] | 979.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day143[N=17,27,20,18] | 1906.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 157 [N=17,22,20,18] | 1145.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 143 [N=16,27,20,18] | 1171.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 125 [N=14,22,16,17] | 855.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day150[N=16,22,23,22] | 1954.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 150[N=16,20,23,22] | 1142.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 129 [N=17,26,21,22] | 958.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 143 [N=16,27,20,18] | 1117.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day157[N=17,22,20,18] | 2129.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 150 [N=16,20,22,23] | 1174.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 136[N=18,24,23,22] | 1266.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day150[N=16,22,23,21] | 1309.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day164[N=16,20,19,21] | 1795.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 All doubles,Day 150[N=16,22,23,21 | 1653.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 All doubles,Day 157[N=17,22,20,18] | 2362.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4Double TNFa,Day 129[N=17,26,21,22] | 755.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane, CD4 Double CD40L,Day304[N=18,28,19,27] | 1664.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 143 [N=16,27,20,18] | 1252.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 150 [N=16,20,23,22] | 1169.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 304 [N=18,28,19,27] | 1054.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day125[N=14,21,15,17 | 1072.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 125[N=14,21,15,17] | 686.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 129 [N=17,26,21,22] | 999.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 157 [N=17,22,20,18] | 1068.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day129[N=17,26,23,22 | 1236.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 136 [N=18,25,19,22] | 1008.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 143[N=17,27,20,18] | 1388.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 164[N=16,19,19,21] | 988.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day136[N=18,24,20,22 | 1559.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double IL-2,Day164[N=16,19,19,21] | 1134.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double TNFa,Day 129[N=17,26,23,22] | 871.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 164 [N=16,19,19,21] | 1089.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day143[N=17,27,20,18 | 1605.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 129 [N=17,24,23,22] | 1008.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IFNg,Day 164 [N=16,19,19,21] | 1090.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Uruguay,CD4 Double IL-2,Day 164 [N=16,19,19,21] | 1028.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day150[N=16,22,23,21 | 1568.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double CD40L,Day 157[N=17,22,20,18] | 1213.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 129[N=17,25,23,22] | 1608.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IL-2,Day 304 [N=18,28,19,27] | 1512.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day157[N=17,22,20,18 | 1284.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | B/Brisbane,CD4 Double IFNg,Day 125 [N=14,22,16,17] | 964.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4Double IFNg,Day 150[N=16,23,22,21] | 1173.0 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/Brisbane,CD4 Double IFNg, Day 136[N=18,24,20,22] | 1681.5 cells/million T cells |
| Placebo/Unadjuvanted Arepanrix Group | Cell-mediated Immunogenicity (CMI) in Terms of Tcell Markers Related to A/California/7/2009, A/Brisbane/59/2007, B/Brisbane/59/2007 and A/Uruguay/716/2007 Antigens | A/California,CD4 Double CD40L,Day164[N=16,19,19,21 | 1215.0 cells/million T cells |
Secondary
Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10. Seropositivity rates of H1N1 HI antibody titers in terms of humoral immune response was pooled by the vaccination received at Day 0 (i.e. Flulaval or Saline placebo) at Days 7, 14, 21 and 122 upto the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.
Time frame: Before vaccination and at Days 7, 14, 21 and 122
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 Flu A/BRI/59/07 H1N1 Day 7 | 54 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 Flu A/BRI/59/07 H1N1 Day 21 | 54 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 Flu A/BRI/59/07 H1N1 Day 14 | 54 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 Flu A/BRI/59/07 H1N1 Day 122 | 54 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 Flu A/BRI/59/07 H1N1 Pre-vaccination | 48 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 Flu A/BRI/59/07 H1N1 Day 122 | 46 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 Flu A/BRI/59/07 H1N1 Pre-vaccination | 44 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 Flu A/BRI/59/07 H1N1 Day 7 | 45 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 Flu A/BRI/59/07 H1N1 Day 14 | 44 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 Flu A/BRI/59/07 H1N1 Day 21 | 44 Subjects |
Secondary
Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.
Time frame: At Days 0 and 304
Population: The According-To-Protocol cohort for immunogenicity at Day 304 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen for blood sample taken at Day 304.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >=1:10 Flu A/BRI/59/07 H1N1 Day 0 (N=21;32;21;27) | 18 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >=1:10 Flu A/BRI/59/07 H1N1 Day 304 (N=21;32;21;27 | 21 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >=1:10 Flu A/BRI/59/07 H1N1 Day 304 (N=21;32;21;27 | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >=1:10 Flu A/BRI/59/07 H1N1 Day 0 (N=21;32;21;27) | 29 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >=1:10 Flu A/BRI/59/07 H1N1 Day 0 (N=21;32;21;27) | 20 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >=1:10 Flu A/BRI/59/07 H1N1 Day 304 (N=21;32;21;27 | 21 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >=1:10 Flu A/BRI/59/07 H1N1 Day 0 (N=21;32;21;27) | 22 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >=1:10 Flu A/BRI/59/07 H1N1 Day 304 (N=21;32;21;27 | 27 Subjects |
Secondary
Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.
Time frame: At Days 122, 129, 136, 143, 150, 157 and 164.
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 122 (N=21;33;25;27) | 21 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 157 (N=20;32;24;25) | 20 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 150 (N=19;31;25;26) | 19 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 129 (N=21;31;25;27) | 21 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 164 (N=21;33;25;27) | 21 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 136 (N=21;33;23;26) | 21 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 143 (N=21;33;25;26) | 21 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 157 (N=20;32;24;25) | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 143 (N=21;33;25;26) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 136 (N=21;33;23;26) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 150 (N=19;31;25;26) | 31 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 164 (N=21;33;25;27) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 129 (N=21;31;25;27) | 31 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 122 (N=21;33;25;27) | 33 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 143 (N=21;33;25;26) | 25 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 122 (N=21;33;25;27) | 22 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 129 (N=21;31;25;27) | 25 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 136 (N=21;33;23;26) | 23 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 150 (N=19;31;25;26) | 25 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 157 (N=20;32;24;25) | 24 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 164 (N=21;33;25;27) | 24 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 136 (N=21;33;23;26) | 26 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 164 (N=21;33;25;27) | 27 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 157 (N=20;32;24;25) | 25 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 129 (N=21;31;25;27) | 26 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 122 (N=21;33;25;27) | 24 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 150 (N=19;31;25;26) | 26 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | >= 1:10 A/BRI/59/07 H1N1 Day 143 (N=21;33;25;26) | 25 Subjects |
Secondary
Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.
Time frame: At Days 122, 129, 136, 143, 150, 157 and 164.
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 122 (N=21;33;25;27) | 12 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 157 (N=20;32;24;25) | 20 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 150 (N=19;31;25;26) | 19 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 129 (N=21;31;25;27) | 20 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 164 (N=21;33;25;27) | 21 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 136 (N=21;33;23;26) | 21 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 143 (N=21;33;25;26) | 21 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 157 (N=20;32;24;25) | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 143 (N=21;33;25;26) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 136 (N=21;33;23;26) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 150 (N=19;31;25;26) | 31 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 164 (N=21;33;25;27) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 129 (N=21;31;25;27) | 26 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 122 (N=21;33;25;27) | 14 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 143 (N=21;33;25;26) | 25 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 122 (N=21;33;25;27) | 13 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 129 (N=21;31;25;27) | 23 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 136 (N=21;33;23;26) | 23 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 150 (N=19;31;25;26) | 25 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 157 (N=20;32;24;25) | 24 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 164 (N=21;33;25;27) | 25 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 136 (N=21;33;23;26) | 26 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 164 (N=21;33;25;27) | 27 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 157 (N=20;32;24;25) | 25 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 129 (N=21;31;25;27) | 23 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 122 (N=21;33;25;27) | 13 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 150 (N=19;31;25;26) | 26 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 A/CAL/7/09 H1N1 Day 143 (N=21;33;25;26) | 26 Subjects |
Secondary
Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10. Seropositivity rates of H1N1 HI antibody titers in terms of humoral immune response was pooled by the vaccination received at Day 0 (i.e. Flulaval or Saline placebo) at Days 7, 14 and 21 upto the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.
Time frame: Before vaccination and at Days 7, 14, 21 and 122
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 Flu A/CAL/7/09 H1N1 Day 7 | 30 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 Flu A/CAL/7/09 H1N1 Day 21 | 36 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 Flu A/CAL/7/09 H1N1 Day 14 | 39 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 Flu A/CAL/7/09 H1N1 Day 122 | 26 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 Flu A/CAL/7/09 H1N1 pre-vaccination | 22 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 Flu A/CAL/7/09 H1N1 Day 122 | 26 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 Flu A/CAL/7/09 H1N1 pre-vaccination | 26 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 Flu A/CAL/7/09 H1N1 Day 7 | 25 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 Flu A/CAL/7/09 H1N1 Day 14 | 26 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >= 1:10 Flu A/CAL/7/09 H1N1 Day 21 | 26 Subjects |
Secondary
Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.
Time frame: At Day 122 and Day 304
Population: The According-To-Protocol cohort for immunogenicity at Day 304 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen for blood sample taken at Day 304.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >=1:10 Flu A/CAL/7/09 H1N1 Day 122 (N=21;32;21;27) | 12 Subjects |
| Flulaval/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >=1:10 Flu A/CAL/7/09 H1N1 Day 304 (N=21;32;21;27) | 21 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >=1:10 Flu A/CAL/7/09 H1N1 Day 304 (N=21;32;21;27) | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >=1:10 Flu A/CAL/7/09 H1N1 Day 122 (N=21;32;21;27) | 14 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >=1:10 Flu A/CAL/7/09 H1N1 Day 122 (N=21;32;21;27) | 11 Subjects |
| Placebo/Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >=1:10 Flu A/CAL/7/09 H1N1 Day 304 (N=21;32;21;27) | 21 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >=1:10 Flu A/CAL/7/09 H1N1 Day 122 (N=21;32;21;27) | 13 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | >=1:10 Flu A/CAL/7/09 H1N1 Day 304 (N=21;32;21;27) | 27 Subjects |
Secondary
Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs).
MAEs refer to events that required medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Related = symptom assed by the investigator as causally related to the study vaccination.
Time frame: Within Days 0-233
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Related MAEs | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Any MAEs | 9 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Any MAEs | 9 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Related MAEs | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Any MAEs | 5 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Related MAEs | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Related MAEs | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Any MAEs | 4 Subjects |
Secondary
Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs).
MAEs refer to events that required medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Related = symptom assed by the investigator as causally related to the study vaccination.
Time frame: During the entire study period (up to Day 507).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Any MAEs | 9 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Related MAEs | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Related MAEs | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Any MAEs | 11 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Any MAEs | 5 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Related MAEs | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Any MAEs | 4 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs). | Related MAEs | 0 Subjects |
Secondary
Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs).
pIMDs are a subset of adverse events (AEs) that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related = symptom assed by the investigator as causally related to the study vaccination.
Time frame: During the entire study period (up to Day 507).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Any pIMDs | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Related pIMDs | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Related pIMDs | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Any pIMDs | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Related pIMDs | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Any pIMDs | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Related pIMDs | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Any pIMDs | 0 Subjects |
Secondary
Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs).
pIMDs are a subset of adverse events (AEs) that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related = symptom assed by the investigator as causally related to the study vaccination.
Time frame: Within Days 0-233
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Any pIMDs | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Related pIMDs | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Related pIMDs | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Any pIMDs | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Any pIMDs | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Related pIMDs | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Any pIMDs | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs). | Related pIMDs | 0 Subjects |
Secondary
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).
SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. Related = symptom assed by the investigator as causally related to the study vaccination.
Time frame: During the entire study period (up to Day 507).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Any SAEs | 3 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Related SAEs | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Related SAEs | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Any SAEs | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Any SAEs | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Related SAEs | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Any SAEs | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Related SAEs | 0 Subjects |
Secondary
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).
SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. Related = symptom assed by the investigator as causally related to the study vaccination. Missing values will be added once they become available.
Time frame: Up to Day 234
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Any SAEs | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Related SAEs | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Related SAEs | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Any SAEs | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Any SAEs | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Related SAEs | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Any SAEs | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs). | Related SAEs | 0 Subjects |
Secondary
Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges.
Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatise (AP), creatinine (CREA), blood urea nitrogen (BUN) and bilirubin (BIL) (total (T) and direct (D)). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).
Time frame: On Days 0, 21, 122 and 164
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 0 Within (N=31,34,33,33) | 31 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 122 Within (N=27;33;26;23 | 27 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-Day 122 Within (N=1,0,0,0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 164 Above (N=1,0,0,0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 164 Within (N=25,33,26,27 | 25 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 122 Below (N=27;33;26;23) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 164 Above (N=25,33,26,27) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 21 Unknown (N=30,34,31,32 | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 0 Within (N=33,34,33,33) | 33 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 122 Within (N=29;33;29;27) | 29 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 122 Within (N=2;0;4;5) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 21 Unknown (N=32,34,31,32 | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 0 Within (N=32,33,33,33) | 32 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 21 Within (N=32,34,31,32) | 32 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 122 Below (N=2;0;4;5) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 122 Within (N=29,33,30,28 | 29 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 164 Within (N=25,33,26,27 | 25 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Above (N=30;33;27;27) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 0 Below (N=2;1;4;5) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 0 Within (N=1,1,0,0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 0 Within (N=2;1;4;5) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Within (N=30;33;27;27) | 25 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 0 Below (N=31;33;29;28) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 0 Above (N=31,34,33,33) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 0 Within (N=31;33;29;28) | 31 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 122 Within (N=0;0;1;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Below (N=30;33;27;27) | 4 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 21 Below (N=2;1;4;5) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 0 Above (N=1,1,0,0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 21 Within (N=2;1;4;5) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Unknown (N=30;33;27;27 | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 164 Within (N=25;33;25;26) | 25 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 21 Unknown (N=31,33,31,32) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 21 Within (N=30,34,31,32) | 30 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 122 Below (N=0;0;1;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 21 Within (N=31,33,31,32) | 31 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 21 Above (N=1,1,0,0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 21 Within (N=32;34;30;31) | 31 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 122 Within (N=28,32,30,28) | 28 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 122 Above (N=1,1,0,0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 21 Above (N=2,0,0,0) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 21 Below (N=32;34;30;31) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 164 Within (N=24,32,26,27) | 24 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 164 Above (N=1,1,0,0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 21 Unknown (N=32;34;30;31) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 0 Within (N=0,1,0,0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 164 Below (N=25;33;25;26) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 0 Within (N=33,33,33,33) | 32 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 122 Within (N=27,33,30,28 | 27 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 21 Within (N=0;0;1;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 0 Above (N=33,33,33,33) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 21 Within (N=0,1,0,0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 164 Above (N=25;33;25;26) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 21 Below (N=0;0;1;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 21 Unknown (N=32,33,31,32 | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 21 Within (N=32,33,31,32) | 28 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 122 Above (N=27,33,30,28) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 0 Within (N=33;34;31;32) | 32 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 21 Above (N=32,33,31,32) | 3 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 122 Within (N=0,1,0,0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 0 Above (N=2,0,0,0) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 0 Below (N=33;34;31;32) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 122 Within (N=29,32,30,28 | 28 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 164 Within (N=0;0;1;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 122 Above (N=29,32,30,28) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 122 Above (N=2,0,0,0) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 0 Within (N=0;0;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 164 Within (N=0,1,0,0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 164 Within (N=25,32,26,27 | 24 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 0 Below (N=0;0;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 164 Above (N=25,32,26,27) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 0 Within (N=32,34,33,33) | 32 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 164 Within (N=24,33,26,27 | 24 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 164 Within (N=23;33;22;22 | 22 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 0 Above (N=32,34,33,33) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-Day 0 Within (N=1,0,0,0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 164 Below (N=23;33;22;22) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 21 Unknown (N=31,34,31,32 | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 122 Above (N=29;33;29;27) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 21 Within (N=31,34,31,32) | 30 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 164 Above (N=24,33,26,27) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 164 Within (N=2;0;4;5) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 21 Above (N=31,34,31,32) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-Day 21 Within (N=1,0,0,0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 164 Below (N=2;0;4;5) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 122 Within (N=28,33,30,28 | 28 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 122 Above (N=28,33,30,28) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 0 Below (N=0;0;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 164 Within (N=2;0;4;5) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 0 Within (N=0,1,0,0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-Day 122 Within (N=1,0,0,0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 164 Within (N=25,32,26,27 | 31 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 122 Below (N=27;33;26;23) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 21 Within (N=0;0;1;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 164 Within (N=25,33,26,27 | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 164 Above (N=1,0,0,0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 0 Above (N=2,0,0,0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 0 Within (N=33,33,33,33) | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 164 Above (N=25,33,26,27) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 164 Within (N=25;33;25;26) | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 122 Within (N=2;0;4;5) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 21 Within (N=31,34,31,32) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 0 Within (N=33,34,33,33) | 34 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 164 Above (N=25,32,26,27) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 0 Above (N=33,33,33,33) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 122 Within (N=27,33,30,28 | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 21 Unknown (N=32,34,31,32 | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 21 Below (N=0;0;1;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 122 Below (N=2;0;4;5) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 122 Above (N=29;33;29;27) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 21 Within (N=32,34,31,32) | 34 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 0 Within (N=32,33,33,33) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 21 Within (N=0,1,0,0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 164 Within (N=23;33;22;22 | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 122 Within (N=29,33,30,28 | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 21 Unknown (N=30,34,31,32 | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Above (N=30;33;27;27) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 122 Within (N=27;33;26;23 | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 164 Within (N=25,33,26,27 | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 122 Within (N=0;0;1;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 0 Within (N=32,34,33,33) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 21 Unknown (N=32,33,31,32 | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 0 Below (N=2;1;4;5) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 164 Within (N=0;0;1;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Within (N=30;33;27;27) | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 0 Within (N=33;34;31;32) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 0 Within (N=2;1;4;5) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 0 Within (N=1,1,0,0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 122 Above (N=28,33,30,28) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 21 Within (N=32,33,31,32) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 0 Below (N=31;33;29;28) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 122 Within (N=28,33,30,28 | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Below (N=30;33;27;27) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 21 Above (N=31,34,31,32) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 0 Within (N=31;33;29;28) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 0 Above (N=32,34,33,33) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 21 Above (N=32,33,31,32) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 122 Above (N=27,33,30,28) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 21 Below (N=2;1;4;5) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 0 Below (N=33;34;31;32) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Unknown (N=30;33;27;27 | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 164 Within (N=24,33,26,27 | 31 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 21 Within (N=2;1;4;5) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 0 Above (N=1,1,0,0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 122 Within (N=0,1,0,0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 164 Below (N=23;33;22;22) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 122 Below (N=0;0;1;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 164 Above (N=24,33,26,27) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 21 Unknown (N=31,33,31,32) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-Day 0 Within (N=1,0,0,0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 122 Within (N=29,32,30,28 | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 164 Above (N=25;33;25;26) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 21 Within (N=31,33,31,32) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 21 Within (N=30,34,31,32) | 34 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 21 Within (N=32;34;30;31) | 34 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 0 Within (N=0;0;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 21 Above (N=1,1,0,0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 0 Above (N=31,34,33,33) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 164 Below (N=2;0;4;5) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 122 Above (N=29,32,30,28) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 122 Within (N=28,32,30,28) | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 164 Below (N=25;33;25;26) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 21 Below (N=32;34;30;31) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 122 Within (N=29;33;29;27) | 33 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 122 Above (N=1,1,0,0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 21 Unknown (N=31,34,31,32 | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-Day 21 Within (N=1,0,0,0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 164 Within (N=0,1,0,0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 164 Within (N=24,32,26,27) | 32 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 21 Above (N=2,0,0,0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 21 Unknown (N=32;34;30;31) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 122 Above (N=2,0,0,0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 164 Above (N=1,1,0,0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 0 Within (N=31,34,33,33) | 33 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 122 Above (N=28,33,30,28) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 0 Within (N=31,34,33,33) | 31 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 0 Above (N=31,34,33,33) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 0 Above (N=2,0,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 21 Unknown (N=30,34,31,32 | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 21 Within (N=30,34,31,32) | 31 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 21 Above (N=2,0,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 122 Within (N=27,33,30,28 | 30 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 122 Above (N=27,33,30,28) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 122 Above (N=2,0,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 164 Within (N=24,33,26,27 | 25 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 164 Above (N=24,33,26,27) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 164 Above (N=1,0,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 0 Within (N=32,33,33,33) | 33 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 0 Within (N=1,1,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 0 Above (N=1,1,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 21 Unknown (N=31,33,31,32) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 21 Within (N=31,33,31,32) | 31 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 21 Above (N=1,1,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 122 Within (N=28,32,30,28) | 30 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 122 Above (N=1,1,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 164 Within (N=24,32,26,27) | 26 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 164 Above (N=1,1,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 0 Within (N=0,1,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 0 Within (N=33,33,33,33) | 32 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 0 Above (N=33,33,33,33) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 21 Within (N=0,1,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 21 Unknown (N=32,33,31,32 | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 21 Within (N=32,33,31,32) | 31 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 21 Above (N=32,33,31,32) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 122 Within (N=0,1,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 122 Within (N=29,32,30,28 | 30 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 122 Above (N=29,32,30,28) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 164 Within (N=0,1,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 164 Within (N=25,32,26,27 | 25 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 164 Above (N=25,32,26,27) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 0 Within (N=32,34,33,33) | 33 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 0 Above (N=32,34,33,33) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-Day 0 Within (N=1,0,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 21 Unknown (N=31,34,31,32 | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 21 Within (N=31,34,31,32) | 31 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 21 Above (N=31,34,31,32) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-Day 21 Within (N=1,0,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 122 Within (N=28,33,30,28 | 29 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-Day 122 Within (N=1,0,0,0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 164 Within (N=25,33,26,27 | 25 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 164 Above (N=25,33,26,27) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 0 Within (N=33,34,33,33) | 33 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 21 Unknown (N=32,34,31,32 | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 21 Within (N=32,34,31,32) | 31 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 122 Within (N=29,33,30,28 | 30 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 164 Within (N=25,33,26,27 | 26 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 0 Below (N=2;1;4;5) | 3 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 0 Within (N=2;1;4;5) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 0 Below (N=31;33;29;28) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 0 Within (N=31;33;29;28) | 29 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 21 Below (N=2;1;4;5) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 21 Within (N=2;1;4;5) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Unknown (N=30;33;27;27 | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Below (N=30;33;27;27) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Within (N=30;33;27;27) | 26 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Above (N=30;33;27;27) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 122 Below (N=2;0;4;5) | 3 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 122 Within (N=2;0;4;5) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 122 Below (N=27;33;26;23) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 122 Within (N=27;33;26;23 | 25 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 164 Below (N=2;0;4;5) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 164 Within (N=2;0;4;5) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 164 Below (N=23;33;22;22) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 164 Within (N=23;33;22;22 | 21 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 0 Below (N=0;0;2;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 0 Within (N=0;0;2;1) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 0 Below (N=33;34;31;32) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 0 Within (N=33;34;31;32) | 31 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 21 Below (N=0;0;1;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 21 Within (N=0;0;1;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 21 Unknown (N=32;34;30;31) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 21 Below (N=32;34;30;31) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 21 Within (N=32;34;30;31) | 30 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 122 Below (N=0;0;1;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 122 Within (N=0;0;1;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 122 Within (N=29;33;29;27) | 29 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 122 Above (N=29;33;29;27) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 164 Within (N=0;0;1;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 164 Below (N=25;33;25;26) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 164 Within (N=25;33;25;26) | 24 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 164 Above (N=25;33;25;26) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 122 Within (N=28,33,30,28 | 28 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 164 Above (N=25;33;25;26) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 122 Within (N=27;33;26;23 | 23 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-Day 21 Within (N=1,0,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 21 Above (N=31,34,31,32) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 122 Within (N=29;33;29;27) | 26 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 164 Below (N=2;0;4;5) | 3 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 21 Within (N=31,34,31,32) | 31 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 21 Unknown (N=31,34,31,32 | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 164 Within (N=24,33,26,27 | 26 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 164 Within (N=2;0;4;5) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-Day 0 Within (N=1,0,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 0 Above (N=32,34,33,33) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 122 Above (N=2,0,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 164 Below (N=23;33;22;22) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 0 Within (N=32,34,33,33) | 33 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 164 Above (N=25,32,26,27) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 164 Within (N=25;33;25;26) | 25 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 164 Within (N=23;33;22;22 | 22 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 164 Within (N=25,32,26,27 | 26 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 164 Within (N=0,1,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 122 Above (N=29;33;29;27) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 0 Below (N=0;0;2;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 122 Above (N=29,32,30,28) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 122 Within (N=29,32,30,28 | 28 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 122 Above (N=27,33,30,28) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 0 Within (N=0;0;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 122 Within (N=0,1,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 21 Above (N=32,33,31,32) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 122 Within (N=27,33,30,28 | 27 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 0 Below (N=33;34;31;32) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 21 Within (N=32,33,31,32) | 31 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 21 Unknown (N=32,33,31,32 | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 0 Above (N=31,34,33,33) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 0 Within (N=33;34;31;32) | 32 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 21 Within (N=0,1,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 0 Above (N=33,33,33,33) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 164 Within (N=0;0;1;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 21 Below (N=0;0;1;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-Day 0 Within (N=33,33,33,33) | 33 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Unknown-Day 0 Within (N=0,1,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 21 Above (N=2,0,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 21 Within (N=0;0;1;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 164 Above (N=1,1,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 164 Within (N=24,32,26,27) | 27 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 21 Within (N=30,34,31,32) | 31 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 21 Unknown (N=32;34;30;31) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 122 Above (N=1,1,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 122 Within (N=28,32,30,28) | 28 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 0 Within (N=31,34,33,33) | 33 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 21 Below (N=32;34;30;31) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 21 Above (N=1,1,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 21 Within (N=31,33,31,32) | 31 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 164 Below (N=25;33;25;26) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-Day 21 Within (N=32;34;30;31) | 30 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 21 Unknown (N=31,33,31,32) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 0 Above (N=1,1,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 21 Unknown (N=30,34,31,32 | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 21 Within (N=2;1;4;5) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 21 Below (N=2;1;4;5) | 4 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 122 Below (N=0;0;1;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Unknown (N=30;33;27;27 | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 0 Within (N=31;33;29;28) | 26 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 0 Below (N=31;33;29;28) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-Day 0 Within (N=1,1,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Below (N=30;33;27;27) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 0 Within (N=2;1;4;5) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 0 Below (N=2;1;4;5) | 3 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-Day 0 Within (N=32,33,33,33) | 33 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Within (N=30;33;27;27) | 24 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 164 Within (N=25,33,26,27 | 27 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 122 Within (N=29,33,30,28 | 28 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 0 Above (N=2,0,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 21 Above (N=30;33;27;27) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 21 Within (N=32,34,31,32) | 31 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 21 Unknown (N=32,34,31,32 | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-Day 122 Within (N=0;0;1;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 122 Below (N=2;0;4;5) | 5 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-Day 0 Within (N=33,34,33,33) | 33 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 164 Above (N=25,33,26,27) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-Day 164 Above (N=1,0,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-Day 122 Within (N=2;0;4;5) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 164 Within (N=25,33,26,27 | 27 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-Day 122 Within (N=1,0,0,0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-Day 164 Above (N=24,33,26,27) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-Day 122 Below (N=27;33;26;23) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-Day 122 Above (N=28,33,30,28) | 0 Subjects |
Secondary
Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges.
Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (AP), creatinine (CREA), blood urea nitrogen (BUN), and bilirubin (BIL) (total (T) and direct (D)). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).
Time frame: At Day 304
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available~N (Number of participants analyzed)= number of subjects with laboratory results for the specified visit and laboratory parameter in a given baseline category Thus, there are subjects with missing results which have not been mentioned here.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Above-D304 Within (N=1;0;0;0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-D304 Within (N=25;31;22;27) | 24 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-D304 Within (N=1;1;0;0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-D304 Within (N=23;31;20;22) | 23 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-D304 Above (N=1;1;0;0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-D304 Within (N=24;32;23;27) | 24 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-D304 Above (N=24;32;23;27) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-D304 Within (N=25;32;23;27) | 25 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-D304 Below (N=0;0;0;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-D304 Within (N=2;0;2;5) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-D304 Within (N=25;31;22;25) | 25 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-D304 Above (N=0;1;1;0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Above-D304 Within (N=0;0;0;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-D304 Within (N=24;32;23;26) | 24 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-D304 Above (N=25;32;23;27) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-D304 Within (N=0;1;1;0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-D304 Above (N=24;32;23;26) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-D304 Below (N=23;31;20;22) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-D304 Within (N=1;0;0;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-D304 Above (N=25;31;22;27) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-D304 Within (N=24;30;22;27) | 24 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-D304 Below (N=2;0;2;5) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-D304 Above (N=24;30;22;27) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-D304 Within (N=2;0;2;5) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-D304 Within (N=25;32;23;27) | 31 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-D304 Above (N=24;32;23;26) | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-D304 Within (N=24;30;22;27) | 30 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-D304 Within (N=1;1;0;0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Above-D304 Within (N=0;0;0;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Above-D304 Within (N=1;0;0;0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-D304 Below (N=2;0;2;5) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-D304 Above (N=1;1;0;0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-D304 Within (N=23;31;20;22) | 30 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-D304 Above (N=24;30;22;27) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-D304 Within (N=0;1;1;0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-D304 Within (N=24;32;23;27) | 31 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-D304 Above (N=25;32;23;27) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-D304 Above (N=24;32;23;27) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-D304 Above (N=25;31;22;27) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-D304 Within (N=24;32;23;26) | 29 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-D304 Within (N=25;31;22;27) | 29 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-D304 Below (N=0;0;0;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-D304 Within (N=1;0;0;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-D304 Above (N=0;1;1;0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-D304 Below (N=23;31;20;22) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-D304 Within (N=25;31;22;25) | 31 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-D304 Above (N=25;32;23;27) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-D304 Below (N=2;0;2;5) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-D304 Within (N=2;0;2;5) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-D304 Below (N=23;31;20;22) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-D304 Within (N=23;31;20;22) | 18 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-D304 Below (N=0;0;0;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-D304 Within (N=25;31;22;25) | 22 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Above-D304 Within (N=0;0;0;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-D304 Within (N=24;32;23;26) | 23 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-D304 Above (N=24;32;23;26) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-D304 Within (N=1;0;0;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-D304 Within (N=24;30;22;27) | 21 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-D304 Above (N=24;30;22;27) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-D304 Within (N=1;1;0;0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-D304 Above (N=1;1;0;0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-D304 Within (N=24;32;23;27) | 23 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-D304 Above (N=24;32;23;27) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Above-D304 Within (N=1;0;0;0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-D304 Within (N=25;31;22;27) | 22 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-D304 Above (N=25;31;22;27) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-D304 Within (N=0;1;1;0) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-D304 Above (N=0;1;1;0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-D304 Within (N=25;32;23;27) | 23 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-D304 Above (N=24;30;22;27) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Within-D304 Within (N=24;30;22;27) | 27 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-D304 Above (N=25;32;23;27) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-D304 Within (N=25;31;22;27) | 27 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Above-D304 Within (N=1;0;0;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-D304 Above (N=24;32;23;26) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILD Baseline Within-D304 Within (N=25;32;23;27) | 27 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Within-D304 Above (N=25;31;22;27) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ALAT Baseline Within-D304 Within (N=24;32;23;26) | 26 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Above-D304 Within (N=0;0;0;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-D304 Within (N=2;0;2;5) | 3 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-D304 Within (N=0;1;1;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Within-D304 Within (N=25;31;22;25) | 25 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BUN Baseline Below-D304 Below (N=0;0;0;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Below-D304 Below (N=2;0;2;5) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | BILT Baseline Above-D304 Above (N=0;1;1;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-D304 Within (N=24;32;23;27) | 27 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-D304 Within (N=23;31;20;22) | 21 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Within-D304 Above (N=24;32;23;27) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-D304 Above (N=1;1;0;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | AP Baseline Above-D304 Within (N=1;1;0;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | CREA Baseline Within-D304 Below (N=23;31;20;22) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges. | ASAT Baseline Above-D304 Within (N=1;0;0;0) | 0 Subjects |
Secondary
Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges.
Laboratory parameters assessed were white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), red blood cells (RBC), hemoglobin (Hgb), hematocrit (Hct) and platelets (PLA). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).
Time frame: At Day 304
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available.~N (Number of participants analyzed)= number of subjects with laboratory results for the specified visit and laboratory parameter in a given baseline category Thus, there are subjects with missing results which have not been mentioned here.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above-D304 Above (N=1;1;0;0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below-D304 Within (N=3;5;5;10) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within-D304 Unknown (N=21;26;16;16) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within-D304 Within (N=21;26;17;25) | 16 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within-D304 Below (N=21;26;16;16) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above-D304 Above (N=1;0;0;0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within-D304 Within (N=21;26;16;16) | 19 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within-D304 Within (N=24;31;21;26) | 22 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Unknown (N=23;28;19;25) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Above (N=23;30;21;22) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above-D304 Within (N=1;1;0;0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below-D304 Below (N=2;1;0;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Within (N=23;30;21;22) | 21 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below-D304 Within (N=2;1;0;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Unknown (N=22;29;21;25) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Below (N=23;30;21;22) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Below (N=22;29;21;25) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Within (N=22;29;21;25) | 18 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Unknown (N=23;30;21;22) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Above (N=22;29;21;25) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above-D304 Within (N=0;1;0;0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below-D304 Within (N=0;1;2;0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below-D304 Unknown (N=0;0;0;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown-D304 Within (N=1;2;1;4) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above-D304 Within (N=1;2;0;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown-D304 Below (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below-D304 Below (N=0;1;2;0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below-D304 Below (N=1;2;1;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below-D304 Within (N=1;2;1;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Unknown (N=23;29;19;24) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown-D304 Below (N=1;1;2;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Below (N=23;29;19;24) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Within (N=23;29;19;24) | 20 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Above (N=23;29;19;24) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Above (N=23;28;19;25) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above-D304 Above (N=1;0;0;0) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above-D304 Within (N=0;0;1;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown-D304 Within (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above-D304 Above (N=0;0;1;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Above (N=23;29;19;26) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above-D304 Above (N=1;2;0;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown-D304 Below (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Within (N=23;29;19;26) | 20 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below-D304 Below (N=2;4;4;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below-D304 Below (N=3;3;2;1) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Below (N=23;29;19;26) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below-D304 Within (N=3;3;2;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within-D304 Unknown (N=24;31;21;26) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within-D304 Unknown (N=21;28;19;25) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Within (N=23;28;19;25) | 20 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Unknown (N=23;29;19;26) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within-D304 Below (N=21;28;19;25) | 3 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below-D304 Within (N=2;4;4;1) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within-D304 Within (N=21;28;19;25) | 16 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below-D304 Within (N=0;2;2;0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below-D304 Below (N=0;2;2;0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within-D304 Unknown (N=24;31;21;26) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within-D304 Unknown (N=21;26;17;25) | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within-D304 Within (N=24;31;21;26) | 21 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below-D304 Unknown (N=0;2;2;0) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within-D304 Above (N=24;31;21;26) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Below (N=23;28;19;25) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within-D304 Below (N=21;26;17;25) | 3 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below-D304 Unknown (N=3;5;5;10) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown-D304 Below (N=1;1;2;1) | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below-D304 Below (N=3;5;5;10) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within-D304 Unknown (N=21;26;17;25) | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within-D304 Below (N=21;28;19;25) | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below-D304 Within (N=3;5;5;10) | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Unknown (N=23;28;19;25) | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Within (N=23;29;19;24) | 27 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within-D304 Unknown (N=21;26;16;16) | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above-D304 Above (N=1;0;0;0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above-D304 Above (N=1;0;0;0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below-D304 Unknown (N=3;5;5;10) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within-D304 Below (N=21;26;16;16) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within-D304 Within (N=21;26;17;25) | 21 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Above (N=23;29;19;24) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below-D304 Within (N=0;2;2;0) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within-D304 Within (N=21;26;16;16) | 22 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Above (N=23;30;21;22) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within-D304 Within (N=21;28;19;25) | 24 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above-D304 Within (N=0;0;1;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below-D304 Within (N=2;4;4;1) | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Above (N=23;29;19;26) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within-D304 Above (N=24;31;21;26) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Within (N=23;30;21;22) | 26 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above-D304 Above (N=0;0;1;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below-D304 Below (N=2;1;0;1) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above-D304 Within (N=1;1;0;0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above-D304 Above (N=1;2;0;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below-D304 Within (N=2;1;0;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within-D304 Within (N=24;31;21;26) | 28 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Below (N=23;30;21;22) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Unknown (N=22;29;21;25) | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below-D304 Within (N=0;1;2;0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within-D304 Unknown (N=24;31;21;26) | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Below (N=22;29;21;25) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above-D304 Within (N=1;2;0;1) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Unknown (N=23;30;21;22) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Within (N=23;29;19;26) | 26 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Within (N=22;29;21;25) | 24 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above-D304 Above (N=1;1;0;0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below-D304 Below (N=0;2;2;0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown-D304 Below (N=1;1;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Above (N=22;29;21;25) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Within (N=23;28;19;25) | 24 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below-D304 Unknown (N=0;0;0;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above-D304 Within (N=0;1;0;0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Below (N=23;28;19;25) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown-D304 Within (N=1;2;1;4) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Below (N=23;29;19;26) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within-D304 Below (N=21;26;17;25) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below-D304 Below (N=0;1;2;0) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below-D304 Below (N=3;3;2;1) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown-D304 Below (N=1;1;2;1) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below-D304 Below (N=2;4;4;1) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within-D304 Unknown (N=24;31;21;26) | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown-D304 Within (N=1;1;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below-D304 Within (N=3;3;2;1) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below-D304 Below (N=1;2;1;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown-D304 Below (N=1;1;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Unknown (N=23;29;19;26) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below-D304 Within (N=1;2;1;1) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Above (N=23;28;19;25) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below-D304 Unknown (N=0;2;2;0) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Unknown (N=23;29;19;24) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within-D304 Unknown (N=21;28;19;25) | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below-D304 Below (N=3;5;5;10) | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within-D304 Within (N=24;31;21;26) | 28 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Below (N=23;29;19;24) | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown-D304 Below (N=1;1;2;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above-D304 Above (N=1;0;0;0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown-D304 Unknown (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within-D304 Unknown (N=24;31;21;26) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within-D304 Within (N=24;31;21;26) | 19 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown-D304 Unknown (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown-D304 Below (N=1;1;2;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below-D304 Below (N=2;4;4;1) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below-D304 Within (N=2;4;4;1) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within-D304 Unknown (N=21;26;17;25) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within-D304 Below (N=21;26;17;25) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within-D304 Within (N=21;26;17;25) | 14 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above-D304 Within (N=1;1;0;0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above-D304 Above (N=1;1;0;0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown-D304 Unknown (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown-D304 Below (N=1;1;2;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below-D304 Below (N=1;2;1;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below-D304 Within (N=1;2;1;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Unknown (N=23;29;19;24) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Below (N=23;29;19;24) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Within (N=23;29;19;24) | 15 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Above (N=23;29;19;24) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above-D304 Within (N=0;0;1;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above-D304 Above (N=0;0;1;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown-D304 Unknown (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown-D304 Below (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown-D304 Within (N=1;1;2;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below-D304 Below (N=3;3;2;1) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below-D304 Within (N=3;3;2;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within-D304 Unknown (N=21;28;19;25) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within-D304 Below (N=21;28;19;25) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within-D304 Within (N=21;28;19;25) | 17 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown-D304 Unknown (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within-D304 Unknown (N=24;31;21;26) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within-D304 Within (N=24;31;21;26) | 19 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within-D304 Above (N=24;31;21;26) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown-D304 Unknown (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below-D304 Unknown (N=3;5;5;10) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below-D304 Below (N=3;5;5;10) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below-D304 Within (N=3;5;5;10) | 3 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within-D304 Unknown (N=21;26;16;16) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within-D304 Below (N=21;26;16;16) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within-D304 Within (N=21;26;16;16) | 14 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown-D304 Unknown (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below-D304 Below (N=2;1;0;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below-D304 Within (N=2;1;0;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Unknown (N=22;29;21;25) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Below (N=22;29;21;25) | 4 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Within (N=22;29;21;25) | 15 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Above (N=22;29;21;25) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above-D304 Within (N=0;1;0;0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown-D304 Within (N=1;2;1;4) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below-D304 Unknown (N=0;0;0;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Unknown (N=23;30;21;22) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Below (N=23;30;21;22) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Within (N=23;30;21;22) | 19 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Above (N=23;30;21;22) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above-D304 Above (N=1;0;0;0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown-D304 Unknown (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown-D304 Below (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown-D304 Within (N=1;1;2;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below-D304 Unknown (N=0;2;2;0) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below-D304 Below (N=0;2;2;0) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below-D304 Within (N=0;2;2;0) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Unknown (N=23;29;19;26) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Below (N=23;29;19;26) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Within (N=23;29;19;26) | 16 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Above (N=23;29;19;26) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown-D304 Unknown (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below-D304 Below (N=0;1;2;0) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below-D304 Within (N=0;1;2;0) | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Unknown (N=23;28;19;25) | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Below (N=23;28;19;25) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Within (N=23;28;19;25) | 17 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Above (N=23;28;19;25) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above-D304 Within (N=1;2;0;1) | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above-D304 Above (N=1;2;0;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below-D304 Below (N=3;5;5;10) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within-D304 Unknown (N=21;26;17;25) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below-D304 Unknown (N=3;5;5;10) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below-D304 Within (N=2;4;4;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown-D304 Below (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within-D304 Above (N=24;31;21;26) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above-D304 Within (N=1;2;0;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within-D304 Within (N=24;31;21;26) | 24 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within-D304 Unknown (N=24;31;21;26) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Below (N=23;28;19;25) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below-D304 Unknown (N=0;2;2;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below-D304 Below (N=2;4;4;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below-D304 Below (N=0;2;2;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within-D304 Within (N=21;28;19;25) | 23 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within-D304 Below (N=21;28;19;25) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown-D304 Within (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below-D304 Within (N=0;2;2;0) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within-D304 Unknown (N=21;28;19;25) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below-D304 Within (N=3;3;2;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Unknown (N=23;29;19;26) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below-D304 Below (N=3;3;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Within (N=23;28;19;25) | 21 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Below (N=23;29;19;26) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown-D304 Below (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown-D304 Below (N=1;1;2;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Within (N=23;29;19;26) | 25 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above-D304 Above (N=0;0;1;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above-D304 Within (N=0;0;1;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within-D304 Above (N=23;29;19;26) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Above (N=23;29;19;24) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Within (N=23;29;19;24) | 23 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Below (N=23;29;19;24) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above-D304 Above (N=1;0;0;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within-D304 Unknown (N=23;29;19;24) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below-D304 Within (N=1;2;1;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below-D304 Below (N=1;2;1;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Above (N=23;28;19;25) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown-D304 Below (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within-D304 Within (N=24;31;21;26) | 24 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below-D304 Below (N=0;1;2;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above-D304 Above (N=1;1;0;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above-D304 Within (N=1;1;0;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown-D304 Within (N=1;2;1;4) | 4 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above-D304 Within (N=0;1;0;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Above (N=22;29;21;25) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within-D304 Unknown (N=24;31;21;26) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below-D304 Unknown (N=0;0;0;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Within (N=22;29;21;25) | 21 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Below (N=22;29;21;25) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below-D304 Within (N=0;1;2;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Unknown (N=23;30;21;22) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within-D304 Unknown (N=22;29;21;25) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below-D304 Within (N=2;1;0;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within-D304 Within (N=21;26;17;25) | 22 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Below (N=23;30;21;22) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below-D304 Below (N=2;1;0;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown-D304 Within (N=1;1;2;1) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within-D304 Below (N=21;26;17;25) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Within (N=23;30;21;22) | 22 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown-D304 Unknown (N=1;1;2;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within-D304 Within (N=21;26;16;16) | 13 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above-D304 Above (N=1;2;0;1) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within-D304 Above (N=23;30;21;22) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within-D304 Below (N=21;26;16;16) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within-D304 Unknown (N=21;26;16;16) | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within-D304 Unknown (N=23;28;19;25) | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above-D304 Above (N=1;0;0;0) | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below-D304 Within (N=3;5;5;10) | 7 Subjects |
Secondary
Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges.
Laboratory parameters assessed were white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), red blood cells (RBC), hemoglobin (Hgb), hematocrit (Hct) and platelets (PLA). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).
Time frame: On Days 0, 21, 122 and 164
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Within | 19 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Below | 6 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Below | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Within | 25 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Below | 3 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Within | 24 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Below | 7 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Within | 30 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Within | 31 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Below | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Below | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Below | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Within | 25 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Within | 31 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Within | 28 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Within | 28 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Within | 31 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Within | 26 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Within | 27 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Below | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Within | 31 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Within | 28 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Within | 33 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Within | 23 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Within | 31 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Above | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Within | 25 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Below | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Within | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Within | 23 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Below | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Below | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Within | 27 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Below | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Within | 23 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Below | 8 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Below | 7 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Within | 30 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Below | 3 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Within | 21 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Within | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Below | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Within | 24 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Within | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Below | 3 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Within | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Within | 19 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Within | 24 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Within | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Within | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Below | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Within | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Within | 21 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Below | 3 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Below | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Within | 25 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Within | 25 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Below | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Above | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Within | 27 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Below | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Below | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Within | 30 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Within | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Below | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Within | 32 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Within | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Within | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Below | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Within | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Within | 29 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Within | 25 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Above | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Within | 29 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Above | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Within | 32 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Below | 2 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Within | 28 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Within | 20 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Below | 4 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Within | 27 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Within | 28 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Below | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Within | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Within | 32 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Within | 33 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Below | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Within | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Unknown | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Below | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Within | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Below | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Within | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Below | 4 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Within | 26 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Below | 4 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Within | 26 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Below | 3 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Within | 26 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Below | 5 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Within | 24 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Below | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Below | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Within | 31 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Above | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Below | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Within | 31 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Within | 29 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Above | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Below | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Within | 30 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Above | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Within | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Within | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Within | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Below | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Within | 33 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Within | 34 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Unknown | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Within | 31 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Above | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Within | 31 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Within | 34 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Within | 34 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Within | 32 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Within | 33 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Below | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Within | 33 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Below | 3 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Within | 31 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Below | 3 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Within | 29 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Below | 7 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Within | 26 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Below | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Within | 33 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Within | 34 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Within | 31 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Above | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Below | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Within | 29 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Above | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Below | 5 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Within | 24 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Above | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Below | 4 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Within | 26 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Above | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Above | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Within | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Within | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Within | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Below | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Within | 31 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Below | 3 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Within | 30 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Below | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Within | 29 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Below | 5 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Within | 27 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Within | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Within | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Within | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Within | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Below | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Within | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Within | 33 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Within | 32 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Above | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Below | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Within | 28 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Above | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Below | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Within | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Below | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Within | 32 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Below | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Within | 31 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Unknown | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Below | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Within | 30 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Below | 5 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Within | 27 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Below | 2 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Within | 30 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Above | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Above | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Within | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Above | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Below | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Within | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Above | 1 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Unknown | 0 Participants |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Above | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Unknown | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Below | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Within | 29 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Within | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Below | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Below | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Within | 28 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Below | 6 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Unknown | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Below | 4 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Within | 23 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Below | 3 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Unknown | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Below | 3 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Within | 22 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Within | 26 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Within | 33 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Unknown | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Within | 23 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Within | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Above | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Within | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Below | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Within | 31 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Unknown | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Below | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Within | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Below | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Within | 23 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Within | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Below | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Below | 4 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Below | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Within | 26 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Within | 30 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Below | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Below | 8 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Within | 25 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Within | 33 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Within | 27 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Above | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Within | 28 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Within | 31 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Above | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Within | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Within | 26 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Within | 17 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Within | 28 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Unknown | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Below | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Above | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Unknown | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Below | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Below | 6 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Within | 31 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Within | 25 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Below | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Within | 25 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Unknown | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Within | 33 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Within | 28 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Within | 16 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Within | 26 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Unknown | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Below | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Within | 20 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Below | 4 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Within | 23 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Unknown | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Below | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Within | 19 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Below | 4 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Below | 8 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Within | 28 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Within | 28 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Below | 6 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Below | 3 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Within | 24 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Below | 3 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Below | 3 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Below | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Within | 29 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Unknown | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Within | 28 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Below | 6 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Below | 4 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Within | 24 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Within | 24 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Unknown | 2 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Within | 22 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Below | 5 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Above | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Within | 22 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Below | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Within | 1 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Below | 8 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Within | 18 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Below | 5 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Below | 3 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Within | 20 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Within | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Within | 31 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Within | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Within | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Unknown | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Within | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Within | 26 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Below | 2 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Within | 4 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Within | 24 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Below | 4 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Within | 33 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Above | 2 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Within | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Unknown | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Within | 32 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Within | 25 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Unknown | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Within | 26 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Above | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Within | 3 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Within | 29 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Within | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Below | 2 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Below | 3 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Above | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Below | 4 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Within | 31 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Below | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Below | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Within | 30 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Within | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 0 | Above | 2 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Below | 4 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Within | 28 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Unknown | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Below | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Within, Day 122 | Below | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Within | 25 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 122 | Above | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Below | 5 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Within | 22 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Within | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Above | 2 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Within | 5 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Within | 18 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Below | 2 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Below | 2 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Within | 12 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Below | 8 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 122 | Unknown | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Within | 14 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Below | 11 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Below | 3 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Within | 29 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Below | 3 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Within | 28 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Unknown | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Below | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Within | 25 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Below | 2 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Within | 24 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Within | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Within | 4 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 21 | Above | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 122 | Above | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | NEU Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Below | 3 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hct Baseline Above, Day 164 | Above | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Within | 27 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 164 | Within | 25 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Within, Day 0 | Within | 22 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Within | 33 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Within | 27 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Within | 27 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Below | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Within | 33 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Within | 29 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Within | 32 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Within | 23 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 21 | Above | 2 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Below | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Unknown | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Unknown | 4 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Within | 32 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Within | 26 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Within, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Within, Day 122 | Above | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Unknown | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Within | 33 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Within | 27 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Within | 27 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | BAS Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Unknown, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Below, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | MON Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Below, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | EOS Baseline Unknown, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 21 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Below | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Within | 32 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Below, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Within | 31 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Below | 2 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Within | 29 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 21 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Unknown | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 0 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Below | 1 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | LYM Baseline Above, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Within | 25 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 122 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Within | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Below | 4 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Within | 22 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | WBC Baseline Below, Day 164 | Below | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Within, Day 164 | Above | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | Hgb Baseline Above, Day 0 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | PLA Baseline Unknown, Day 122 | Unknown | 0 Participants |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges. | RBC Baseline Within, Day 21 | Below | 0 Participants |
Secondary
Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group.
Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature (= axillary temperature equal to or above 38.0 degrees Celsius (°C)) and were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine. Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = axillary temperature above 39.0°C.
Time frame: During the 7-day (Days 0-6) follow-up period after vaccination.
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Fatigue | 9 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Fatigue | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Fatigue | 9 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Headache | 7 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Headache | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Headache | 7 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Joint pain at other location | 4 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Joint pain at other location | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Joint pain at other location | 4 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Muscle aches | 8 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Muscle aches | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Muscle aches | 8 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Shivering | 3 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Shivering | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Shivering | 3 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Sweating | 5 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Sweating | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Sweating | 5 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Fever ≥ 38.0°C | 2 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Fever ≥ 39.0°C | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Fever | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Muscle aches | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Sweating | 4 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Sweating | 4 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Joint pain at other location | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Muscle aches | 12 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Joint pain at other location | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Shivering | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Shivering | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Fatigue | 12 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Fever ≥ 39.0°C | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Sweating | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Shivering | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Headache | 10 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Joint pain at other location | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Headache | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Fatigue | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Fever | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Muscle aches | 12 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Headache | 11 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Fatigue | 13 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Fever ≥ 38.0°C | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Fatigue | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Headache | 9 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Joint pain at other location | 9 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Sweating | 4 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Joint pain at other location | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Joint pain at other location | 9 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Muscle aches | 12 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Muscle aches | 3 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Fever ≥ 38.0°C | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Muscle aches | 12 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Shivering | 5 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Fever | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Shivering | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Shivering | 5 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Fever ≥ 39.0°C | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Sweating | 4 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Fatigue | 12 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Fatigue | 12 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Sweating | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Headache | 9 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Headache | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Sweating | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Muscle aches | 5 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Sweating | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Fatigue | 8 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Fever ≥ 39.0°C | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Joint pain at other location | 3 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Muscle aches | 5 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Fatigue | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Sweating | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Joint pain at other location | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Headache | 8 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Fatigue | 8 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Fever | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Shivering | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Shivering | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Fever ≥ 38.0°C | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Joint pain at other location | 3 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Related Shivering | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Headache | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Grade 3 Muscle aches | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group, Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group. | Any Headache | 8 Subjects |
Secondary
Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group.
Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature (= axillary temperature equal to or above 38.0 degrees Celsius (°C)) and data collected was pooled by administration of vaccination received at Day 0 (i.e. Flulaval or Saline placebo). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = axillary temperature above 39.0°C.
Time frame: During the 7-day (Days 0-6) follow-up period after vaccination.
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Fatigue | 18 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Fatigue | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Fatigue | 15 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Headache | 19 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Headache | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Headache | 17 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Joint pain at other location | 13 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Joint pain at other location | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Joint pain at other location | 11 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Muscle aches | 20 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Muscle aches | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Muscle aches | 18 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Shivering | 8 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Shivering | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Shivering | 8 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Sweating | 9 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Sweating | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Sweating | 8 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Fever ≥ 38.0°C | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Fever ≥ 39.0°C | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Fever | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Muscle aches | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Fatigue | 7 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Fever ≥ 38.0°C | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Fatigue | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Muscle aches | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Fatigue | 7 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Sweating | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Headache | 4 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Shivering | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Headache | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Fever | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Headache | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Shivering | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Joint pain at other location | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Sweating | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Joint pain at other location | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Shivering | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Related Joint pain at other location | 2 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Grade 3 Fever ≥ 39.0°C | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Muscle aches | 3 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited General Symptoms From Flulaval Group and Placebo Group. | Any Sweating | 1 Subjects |
Secondary
Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group
Solicited local symptoms assessed were pain, redness and swelling and were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal activity. Grade 3 redness and swelling were defined as redness/swelling above 100 millimeter (mm).
Time frame: During the 7-day (Days 0-6) follow-up period after vaccination.
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Any Pain | 19 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Grade 3 Pain | 4 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Any Redness | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Grade 3 Redness | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Any Swelling | 3 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Grade 3 Swelling | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Grade 3 Swelling | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Grade 3 Redness | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Any Pain | 14 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Any Redness | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Grade 3 Pain | 1 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Any Swelling | 1 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Grade 3 Pain | 4 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Any Redness | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Grade 3 Redness | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Grade 3 Swelling | 0 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Any Swelling | 2 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Any Pain | 24 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Any Swelling | 1 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Grade 3 Swelling | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Grade 3 Pain | 2 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Grade 3 Redness | 0 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Any Pain | 10 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval/Arepanrix Group,Flulaval/Unadjuvanted Arepanrix Group,Placebo/Arepanrix Group and Placebo/Unadjuvanted Arepanrix Group | Any Redness | 0 Subjects |
Secondary
Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group.
Solicited local symptoms assessed were pain, redness and swelling and data collected was pooled by administration of vaccination received at Day 0 (i.e. Flulaval or Saline placebo). Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal activity. Grade 3 redness and swelling were defined as redness/swelling above 100 millimeter (mm).
Time frame: During the 7-day (Days 0-6) follow-up period after vaccination.
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | Any Pain | 35 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | Grade 3 Pain | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | Any Redness | 4 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | Grade 3 Redness | 0 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | Any Swelling | 1 Subjects |
| Flulaval/Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | Grade 3 Swelling | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | Any Swelling | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | Any Pain | 5 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | Grade 3 Redness | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | Grade 3 Pain | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | Grade 3 Swelling | 0 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Solicited Local Symptoms From Flulaval Group and Placebo Group. | Any Redness | 0 Subjects |
Secondary
Number of Subjects Reporting Unsolicited AEs.
Unsolicited AEs were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine. An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Time frame: Within 84 days following first dose or 63 days following second dose of vaccine.
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Unsolicited AEs. | 9 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Unsolicited AEs. | 8 Subjects |
| Placebo/Arepanrix Group | Number of Subjects Reporting Unsolicited AEs. | 7 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Unsolicited AEs. | 5 Subjects |
Secondary
Number of Subjects Reporting Unsolicited AEs.
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Unsolicited AEs were collected after the administration of the Flulaval vaccine or the placebo dose and the data has been pooled based on the vaccination received at Day 0.
Time frame: Up to 21-day (Days 0-20) after vaccination
Population: The Total Vaccinated cohort included all vaccinated subjects for whom data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flulaval/Arepanrix Group | Number of Subjects Reporting Unsolicited AEs. | 13 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Number of Subjects Reporting Unsolicited AEs. | 12 Subjects |
Secondary
Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
Titers were expressed as geometric mean antibody titers (GMTs).
Time frame: At Day 0 and Day 304
Population: The According-To-Protocol cohort for immunogenicity at Day 304 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen for blood sample taken at Day 304.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 0 | 19.3 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 304 | 129.0 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 304 | 114.4 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 0 | 25.6 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 0 | 21.6 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 304 | 48.0 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 0 | 18.2 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 304 | 37.0 Titers |
Secondary
Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
Titers were expressed as geometric mean antibody titers (GMTs).
Time frame: At Days 122, 129, 136, 143, 150, 157 and 164.
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 150 (N=19;31;25;26) | 146.1 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 164 (N=21;33;25;27) | 144.9 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 136 (N=21;33;23;26) | 144.9 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 157 (N=20;32;24;25) | 144.2 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 143 (N=21;33;25;26) | 140.3 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 122 (N=21;33;25;27) | 135.6 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 129 (N=21;31;25;27) | 140.4 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 136 (N=21;33;23;26) | 144.1 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 164 (N=21;33;25;27) | 123.1 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 129 (N=21;31;25;27) | 126.5 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 122 (N=21;33;25;27) | 125.7 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 157 (N=20;32;24;25) | 131.5 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 143 (N=21;33;25;26) | 129.6 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 150 (N=19;31;25;26) | 138.2 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 143 (N=21;33;25;26) | 38.8 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 122 (N=21;33;25;27) | 18.4 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 129 (N=21;31;25;27) | 27.0 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 157 (N=20;32;24;25) | 49.6 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 150 (N=19;31;25;26) | 44.0 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 136 (N=21;33;23;26) | 44.4 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 164 (N=21;33;25;27) | 49.2 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 164 (N=21;33;25;27) | 35.2 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 122 (N=21;33;25;27) | 18.0 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 129 (N=21;31;25;27) | 24.4 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 143 (N=21;33;25;26) | 35.4 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 150 (N=19;31;25;26) | 34.5 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 157 (N=20;32;24;25) | 33.8 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT A/BRI/59/07 H1N1 Day 136 (N=21;33;23;26) | 38.9 Titers |
Secondary
Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
Titers were expressed as geometric mean antibody titers (GMTs). GMTs of H1N1 HI antibody titers in terms of humoral immune response was pooled by the vaccination received at Day 0 (i.e. Flulaval or Saline placebo) at Days 7, 14, 21 and 122 upto the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.
Time frame: Before vaccination and at Days 7, 14, 21 and 122
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 7 | 65.5 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 21 | 200.3 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 14 | 213.6 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 122 | 129.4 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 pre-vaccination | 23.3 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 122 | 18.1 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 pre-vaccination | 18.7 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 7 | 18.3 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 14 | 18.4 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | GMT Flu A/BRI/59/07 H1N1 Day 21 | 18.8 Titers |
Secondary
Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
Titers were expressed as geometric mean antibody titers (GMTs).
Time frame: At Days 122 and 304
Population: The According-To-Protocol cohort for immunogenicity at Day 304 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen for blood sample taken at Day 304.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 122 | 16.1 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 304 | 157.4 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 304 | 100.3 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 122 | 12.8 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 122 | 15.6 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 304 | 289.9 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 122 | 12.9 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 304 | 116.0 Titers |
Secondary
Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
Titers were expressed as geometric mean antibody titers (GMTs). GMTs of H1N1 HI antibody titers in terms of humoral immune response was pooled by the vaccination received at Day 0 (i.e. Flulaval or Saline placebo) at Days 7, 14, 21 and 122 upto the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.
Time frame: Before vaccination and at Days 7, 14, 21 and 122
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 7 | 14.8 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 21 | 17.8 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 14 | 19.9 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 122 | 13.8 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 pre-vaccination | 12.5 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 122 | 13.4 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 pre-vaccination | 13.9 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 7 | 13.8 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 14 | 13.8 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 21 | 13.3 Titers |
Secondary
Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
Titers were expressed as geometric mean antibody titers (GMTs).
Time frame: At Days 122, 129, 136, 143, 150, 157 and 164.
Population: The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 122 (N=21;33;25;27) | 16.1 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 157 (N=20;32;24;25) | 651.3 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 150 (N=19;31;25;26) | 452.8 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 129 (N=21;31;25;27) | 66.7 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 164 (N=21;33;25;27) | 650.7 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 136 (N=21;33;23;26) | 491.6 Titers |
| Flulaval/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 143 (N=21;33;25;26) | 390.1 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 157 (N=20;32;24;25) | 303.2 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 143 (N=21;33;25;26) | 256.6 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 136 (N=21;33;23;26) | 303.7 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 150 (N=19;31;25;26) | 292.7 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 164 (N=21;33;25;27) | 259.4 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 129 (N=21;31;25;27) | 54.6 Titers |
| Flulaval/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 122 (N=21;33;25;27) | 12.5 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 143 (N=21;33;25;26) | 557.3 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 122 (N=21;33;25;27) | 13.9 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 129 (N=21;31;25;27) | 83.3 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 136 (N=21;33;23;26) | 602.5 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 150 (N=19;31;25;26) | 565.0 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 157 (N=20;32;24;25) | 818.1 Titers |
| Placebo/Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 164 (N=21;33;25;27) | 799.0 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 136 (N=21;33;23;26) | 385.6 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 164 (N=21;33;25;27) | 332.7 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 157 (N=20;32;24;25) | 338.2 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 129 (N=21;31;25;27) | 70.3 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 122 (N=21;33;25;27) | 12.9 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 150 (N=19;31;25;26) | 333.3 Titers |
| Placebo/Unadjuvanted Arepanrix Group | Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | GMT Flu A/CAL/7/09 H1N1 Day 143 (N=21;33;25;26) | 365.6 Titers |
Secondary
Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.
VRR for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. The cut-off value for microneutralization titers is 1:28.
Time frame: For the entire study period up to Day 507
Population: The According-To-Protocol cohort for immunogenicity at Day 304 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at Day 304.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flulaval/Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 14 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 16 Subjects |
| Placebo/Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 3 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain. | 7 Subjects |
Secondary
Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.
VRR for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. The cut-off value for microneutralization titers is 1:28.
Time frame: Entire study period up to Day 507
Population: The According-To-Protocol cohort for immunogenicity at Day 304 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at Day 304.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flulaval/Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 13 Subjects |
| Flulaval/Unadjuvanted Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 14 Subjects |
| Placebo/Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 17 Subjects |
| Placebo/Unadjuvanted Arepanrix Group | Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. | 17 Subjects |